Subject Index For Volume 33

Abdominal aneurysm, renal injury (abst) 623Ablation

anemia lessens hypertension and proteinuria (abst) . . . 375deep nephrons (abst) 374

AcetatecAMP (abst) 219succinate, effects in dialysis (abst) 228

Acetazolamidediabetic nephropathy (abst) 209kinetics of anion exchange inhibitor (abst) 406pH, transport (abst) 157

Acidamino, keto, disturbances of metabolism in RF (abst).. 139amino, keto in diet for CRF (abst) 138

Acid-baseabnormalities in cardiopulmonary arrest (abst) 185status and dialysis symptoms 24:S-l17status in ESRD (abst) 246

AcidificationCsA in heart transplant (abst) 440IMCD adaptation (abst) 398proton locating ATPase 767

Acidosisacidification defect in distal renal tubular (abst) 130ammonium excretion (abst) 183carbicarb vs. bicarbonate in treatment (abst) 407flow rate determines bicarbonate reabsorption (abst). .. 404GLA protein and bone films in HD (abst) 232glucose reabsorption, hyperglycemia (abst) 201hyperchioremic (abst) 1040interaction of glutamine and glutathione (abst) 390metabolic, adaptation in BLM (abst) 405metabolic, H-ATPase (abst) 404metabolic, HCO3 reabsorption (abst) 404metabolic, K depletion (abst) 405Na dependent, distal acidification (abst) 194

phosphoenolpyruvate carboxykinase (abst) 177

respiratory (abst) 402stimulates endocytic activity in CCD (abst) 406

Acinetobacter peritonitis (abst) 246Actetate

muscle high energy metabolites during HD (abst) 240Acute Hantavirus nephropathy (abst) 356Acute pancreatitis diagnosis (abst) 183Acute renal failure

after transplantation, perfused allograft (abst) 450

aminoglycoside nephrotoxicity 900analgesic drugs (abst) 352Aug II augments hypoxia (abst) 354artery reconstruction (abst) 136CAVH 24:S-159CAVH in 100 patients (abst) 757clearance of calcitriol 530coagulation defects in uremia 24:S-l3deferoxamine (abst) 363djenkolic acid induced (abst) 359DNA synthesis and polymerase activity (abst) 623endotoxemic ARF, role of PAF (abst) 358

xl

focus of tissue necrosis and gentamicin 84glycerol induced, HgCl2 nephrotoxicity (abst) 352histopathology of ischemic (abst) 366hydroxyl radical in glycerol induced (abst) 368hypoperfusion, gentamicin (abst) 357induction and prevention of media-induced 699mannitol induced (abst) 188

methylguanidine (abst) 371

nephrotoxic, loop diuretics (abst) 364newborn, treatment (abst) 226plasma exchange in multiple myeloma 1175post-ischemia (abst) 369reactive oxygen species do not mediate ischemic

(abst) 370renal recovery and survival (abst) 238requiring dialysis (abst) 756saline loading in uranium-induced 942theophylline use in post-ischemic 24urine sediment, childhood (abst) 1041vasa recta blood flow (abst) 369proto-oncogene expression (abst) 152

Acute renal insufficiencytheophylline prevents hypoxemia-induced changes . .. 1078

Acute tubular necrosisclearance of calcitriol 530culture of cells from urine (abst) 364HgCl2 and K2Cr2O7 induced (abst) 365

AdenosineAl analog, TGF (abst) 263analogues, tubuloglomerular feedback (abst) 413cGMP a second messenger in renin inhibition 798deaminase, ischemia (abst) 367nucleotides in azotemic rabbits (abst) 382receptor localization (abst) 256renal function and vasa recta blood flow (abst) 276triphosphate, thymidine incorporation (abst) 3892C1, cAMP production and Na transport (abst) 419

Adenylate cyclaseAVP in aging human CT (abst) 290lithium (abst) 265monoclonal antibody 543mutations in Gs alpha (abst) 166

ADHglycerophosphoryicholine (abst) 255inhibition, diuresis (abst) 432

Adhesive glycoproteinsfibronectin (abst) 154

ADPKDadenocarcinoma, chronic HD (abst) 1040continuous tissue culture (abst) 191

cystic kidneys 610diphenyithiazole 1130genetic marker for diagnosis (abst) 625hyperuricemia in (abst) 211influence of sex on liver disease (abst) 196

screening protocol (abst) 191

Adriamycininduced NS (abst) 261

Subject Index: Vol. 33 xli

nephropathy, captopril and diltiazem (abst) 382

nephrosis, protein restriction (abst) 380Aerobics in obese Zucker rats (abst) 326

Agecatecholamaine receptor binding 1073desensitization to PTH (abst) 348diet and sex response to immune injury 561

disease diagnosis, IgA (abst) 196

quality of life of old dialysis patients (abst) 758reduction in cytosolic Ca2 response (abst) 338

Agenesis vs. nephrectomy (abst) 143, 195AIDS

ARC and nephrotic syndrome (abst) 210associated nephropathy not in San Francisco (abst) . . . 202FSGS during (abst) 1041HIV antibodies in Danish dialysis patients (abst) 756HIV associated focal, segmental sclerosis (abst) 330HIV infections in HD (abst) 230HIV testing in chronic HD (abst) 235HIV transmission during HD (abst) 233hyponatremia, ARC (abst) 211nephropathy as initial manifestation (abst) 205peritonitis in HIV infected CAPD patients (abst) 245rapid renal failure (abst) 198

Alanine flux, CRF (abst) 395Albumin

extrarenal complications in nephrotic syndrome 1184

gene transcription (abst) 156

glycation of 673hemodynamics of excretion (abst) 434mild charge modification, excretion (abst) 433mild charge modification on excretion (abst) 1039optimal determination of excretion in diabetics

(abst) 214progressive decrease of in CAPD (abst) 757synthesis with dietary protein restriction (abst) 379synthesis, dietary protein (abst) 378

Albuminuriainsulin-dependent diabetes mellitus 100

lysozymuria in Heymann's nephritis 787protein or enalapril (abst) 377

Alcohol abuse, mes IG deposition (abst) 385Aldose reductase

sorbitol in maintaining the medullary intracellularmilieu 635

AldosteroneADH, electrolytes (abst) 283

ATPase activity (abst) 278

biochemical pathway of (abst) 276

chronic acid loading (abst) 401

high potassium intake (abst) 270

K adaptation (abst) 427K and kaliuresis after acute loading of K (abst) 1037mechanism of increase in K conductance (abst) 429PCO2 enhance vanadate RB absorption (abst) 423voltage gated Ca currents in adrenal cells (abst) 291

19-nor, urinary excretion (abst) 273

Alfacalcidol, Ca iones (abst) 334Alkali secretion into urine (abst) 399Alkaline phosphatase in kidney (abst) 176Alkalosis

acute respiratory, PG (abst)calcium retention (abst)chloride depletion in KCl depletion (abst)chloride depletion metabolic (abst)

chronic neutral phosphate infusion (abst) 401distal nephron maintains chloride-deplete (abst) 409

PhCo3 in K-depletion (abst) 402response to bumetanide (abst) 200

Allograftbiopsies compared (abst) 440cadaver donor age and survival of (abst) 450

CD4+ specific suppressor cell (abst) 443

dietary protein restriction, CsA, rejection (abst) 1038

dysfunction, eosinophils (abst) 453factors influencing function (abst) 454glutathione transferase in urine 571

inflammatory cells, /32M and thromboxane (abst) 442long term predictors of survival (abst) 448monotored by plasma neopterin levels (abst) 453serum 11-2 (abst) 453survival determinants (abst) 444tolerance (abst) 447

Allopurinol, ischemia (abst) 396Alpha human natriuretic peptide

response to in CRF (abst) 287

Alpha-adrenergic agonist, 02 (abst) 392

Alpha-galactosidase, Fabry's (abst) 182

Alpha-hydroxylaseactivity, PTH (abst) 338

vitamin D3 (abst) 336Alpha- 1 -adrenergic

stimulation of diacyglycerol production (abst) 388

Alpha2 adrenoceptormediated vasoconstriction (abst) 414

Aluminumbone disease in children on CAPD or CCPD 975

erythropoiesis, deferoxamine (abst) 215hair and serum, in children with CRF (abst) 139

improvement in microcytic anemia (abst) 215induced osteomalacia, PTH (abst) 343infusion on PTH release (abst) 336iron overload in chronic dialysis 24:S-163microcytic anemia (abst) 349

phosphate 24:S-172phospholipid content of BBMV (abst) 350PTH in transplantation (abst) 346PTH secretion in HD, Ca (abst) 231

PTH secretion, Ca (abst) 337

removal, membranes compared 24:S-171resistance to recombinant human erythropoietin

(abst) 240serum, monitoring in HD (abst) 218vitamin D3 increases plasma, HD 24:S-l75

Ambulatory peritoneal dialysisintermittent (abst) 244

Ambystomadiluting segment (abst) 419

PT, Cl— transport (abst) 423Amikacin toxicity in rat neonates 36Amiloride

binding site, lysine group, NaIH antiporter (abst) 401

Ca absorption by (abst) 341

sensitive urea transport (abst) 4335-(N-methyl-N-isobutyl) (abst) 399

Amino acidinduced rise in hemodynamics, glucagon and PGE .. . 1147

metabolism, hepatic glucose, uremia (abst) 356sequences in mouse and bovine ACE homology 652

transport (abst) 432

401338402400

xlii Subject Index: Vol. 33

uptake, adaptive response to (abst) 417Aminoglycoside

and ARF 84nephrotoxicity 900

Aminonucleoside nephrosistubulointerstitial nephritis 14

Ammoniaproduction by perfused PT (abst) 405

Ammoniagenesisgamma glutamyltransferase, PAH (abst) 397gamma-glutamyltransferase (abst) 391glutamine, benzoate (abst) 392pH and NH1 metabolism in LLC-PKI cells (abst) 394PTH (abst) 389

Ammoniagenic pathways, 15N (abst) 167Ammonium

ion absorption by TAL (abst) 400ionic exit from tubule (abst) 407

Amphotericin Bcoccidioidomycosis(abst) 193toxicity (abst) 360

Amyloid arthropathy, RDT (abst) 626Amyloidosis

A characterization (abst) 330asymptomatic dialysis patients (abst) 236biocompatibility phenomenon of HD 24:S-35dialysis associated with long-term HD (abst) 234dialysis related 24:S-32HD associated (abst) 231

Analgesicdrugs, tubular damage (abst) 352nephropathy, biopsies in (abst) 145nephropathy, proteinuria is glomerular (abst) 141syndrome (abst) 136

Analogs of vitamin D3 (abst) 339Anaphylatoxin adsorption, HD (abst) 226Androgen

regulation of antiotensinogen messenger RNA (abst). . . 262Anemia

correction in chronic HD (abst) 237correction in hemodialysis (abst) 189erythropoiesis and erythropoietin blood levels (abst). . . 372erythropoietin, hemoglobin (abst) 217ESRD 983exercise capacity in HD (abst) 206human erythropoietin, hemodialysis (abst) 204hypertension and proteinuria in ablation (abst) 375microcytic, Al induced in HD (abst) 215peroxidation of polyunsaturated fatty acids (abst) 624recombinant human erythropoietin (abst) 232rHuEPO in HD (abst) 623risk factor in kidney biopsies (abst) 202

Angioplasty in elderly, RF (abst) 203Angiotensin

pressure-natriuresis relationship (abst)renin in hybridization (abst)renin, gene expression in (abst)tubuloglomerular feedback responses (abst)urinary excretion a marker of renal production

(abst) 1036Angiotensin converting enzyme

acute inhibition of (abst) 757cDNA isolation (abst) 150eliminatin of hippuran in RAS (abst) 760enalapril in diabetic nephropathy (abst) 178

hydroosmotic action of AVP (abst) 284inhibition, arterial stenosis (abst) 306inhibition, renal artery stenosis 1038inhibitor, suppresses growth of cells (abst) 296inhibitor, urea excreation (abst) 196partial protein sequence of mouse and bovine 652protein restriction, nephrosis (abst) 188reversible depression of Na,K-ATPase (abst) 303role in glomerulo-tubular balance (abst) 421

Angiotensin Iconverting enzyme, GFR (abst) 259

Angiotensin IIasymmetric reduction of receptor sites (abst) 304AVP in vascular smooth muscle cells (abst) 151

blockade reduces proteinuria (abst) 383causes formation of PAF (abst) 278CE!, reduced renal mass (abst) 384control of early proximal acidification (abst) 398disordered receptor regulation, diabetes (abst) 302down regulation of receptors in VSM (abst) 288hypertension (abst) 382Na reabsorption (abst) 129PGI on hemodynamics (abst) 413phospholipase A2, GTP binding protein (abst) 154platelet receptors, HD (abst) 230receptors and eicosanoid production (abst) 257sorbinil (abst) 380streptozotocin-induced diabetes (abst) 380thromboxane responses to (abst) 30812-lipoxygenase products (abst) 173

Angiotensinogenproduction by PTC (abst) 291role in glomerulo-tubular balance (abst) 421

Anionarginyl and histidyl groups (abst) 438

Anion exchanger, band 3 (abst) 168Anionic sites in MGN (abst) 627Ankyrin, spectrin and Na,K-ATPase (abst) 167Anoxia

alterations in Ca compartmentation (abst) 361cytosolic free Ca in renal damage (abst) 359metabolic responses to, hypoxia (abst) 390

Anti-GBM diseasequantitation oLantibody (abst) 135

Antibodiesand lectin staining for glomerular cells (abst) 159anti-endothelial cell, IgAN (abst) 334anti-GBM, anti-neutrophil cytoplasm, nephritis

(abst) 329anti-heparan sulfate proteoglycan (abst) 320anti-phospholipid, lupus nephritis (abst) 328circulating DNA and lupus nephritis 487epitope specific induction of proteinuria by 831

etylendioxid IgE (abst) 755glomerular, in human anti-GBM disease (abst) 135

Heymann nephritis antigen (abst) 251HLA removed in dialysis (abst) 4431gM anti-neutrophil, pulmonary hemorrhage (abst) .... 328immune complexes formation (abst)immune deposits in cryoglobulinemia (abst)induced mesangial cell lysis (abst)monoclonal anti-idiotype, DNA (abst)monoclonal, myeloma cast nephropathy (abst)monoclonal, nucleated cells in urine sediment (abst).new antigen system in progressive RF (abst)

411169163411

312626327199328332333

Subject Index: Vol. 33 xliii

noncationized, immune complexes (abst) 315

polyreactive anti-DNA, lupus nephritis (abst) 331serological diagnosis of Wegener' s granulomatosis

(abst) 760SGP-1151107, induction of proteinuria 818

Antidigoxin antibody, Na,K ATPase (abst) 383Antidiuresis

euglycemic insulin, chloride handling (abst) 271Antidiuretic hormone

nephron function by micropuncture (abst) 141

Antigenantibodies interact with, glomerular epithelial (abst) . . . 314binding, surface charge distribution (abst) 310clearance of immune complex (abst) 320GP600, glycoproteins in Heymann nephritis (abst) 164monoclonal anti-DNA antibodies (abst) 323non-GBM glomerular capillary wall, antibody to

(abst) 144

secreting epithelial cells (abst) 317streptococcal nephritogenic, complement activation

(abst) 144tubular, associated renal disease, injury (abst) 131

Antioxidant therapy, ischemia (abst) 353

AntiportNa/H and sodium chloride (abst) 157racial difference (abst) 297

system, polarized (abst) 406Antiporter

activity, renal nerves (abst) 420enhancement of Na-H in chronic hypercapnia (abst). . . 407Na-H, phorbol-ester stimulates(abst) 428genetic marker for diagnosis (abst) 625

Apical membrane activation, cAMP (abst) 427APKD

anatomy of renin-secreting cell 1084

dietary protein (abst) 315histochemical studies (abst) 333linked DNA marker (abst) 184natriuretic response to volume expansion (abst) 211progressive, liver lesions in (abst) 192

reducing cyst volume (abst) 181

surgical anatomy of liver (abst) 202

Apoferritin, ICGN (abst) 314Arachidonic acid

diabetic rat (abst) 393P-450 (abst) 162

Arginine vasopressinACE inhibitors (abst) 284ADH and urea therapy (abst) 130AT! desensitization (abst) 151

bombesin (abst) 282

cAMP, pertussis toxin, somatostatin inhibition 536

dopaminergic stimuli (abst) 283gene expression in heart failure (abst) 270gene regulation in HBR (abst) 285

glucose uptake and oxidation (abst) 390286267306

mesangial cell replication (abst)14,15 dihydroxyeicosatrienoic acid (abst)

Arterial stenosis, ACE (abst)Arterioles

vasopressin selectively contracts (abst) 262Arteriovenous fistulas (abst) 761

Arteryreconstruction in renal failure patients (abst) 136

Arthritisoverview of pediatric nephropathology.

Artificial atria, ventricles, ANF (abst) . .

Ascitesintractable, ascitic ultrafiltration (abst)

Ascitis, paracentesis (abst)Aspirin, lupus nephritis (abst)Atenolol, exercise, hypertension (abst) .Atherogenic role of vitamin D3 (abst)Atherosclerosis, FSGSATP

ion transport systems (abst) 173ATPase

aldosterone (abst) 278

Ca absorption (abst) 347C1 dependent H (abst) 159oxygen free radical (abst) 1038

proton locating 767proton translocating in IMCD (abst) 408uremic factor inhibits RBC (abst) 222

Atrial natriuretic factorAng II, phosphoinositide changes (abst) 253antagonizes PGE2 release (abst) 279calves, artificial atria (abst) 290

captopril, hypertension (abst) 277cerebrospinal fluid concentrations (abst) 256clearance receptors (abst) 279

CyA nephrotoxicity (abst) 356heart failure (abst) 262high-output heart failure 656

hypotensive hemorrhage (abst) 369mineralocorticoid escape (abst) 430myocytes in fish (abst) 253Na excretion (abst) 284natriuresis (abst) 258osmotic water permeability (abst) 278plasma concentration in pregnancy (abst) 140poorly controlled diabetes (abst) 254post-ischemic acute failure (abst) 363

pregnancy (abst) 257

saline-expanded dogs (abst) 266salt adaptation in fish (abst) 289sodium retention during heart failure (abst) 272valsalva maneuver (abst) 2691-30 and 31-67 circulate in human (abst) 284

Atrial natriuretic peptideANF, dopamine, renal ischemia (abst) 259anti-ANP antibody, congestive heart failure (abst) 253augments excretion of Pi and Na (abst) 279blood glucose in insulin-dependent diabetes (abst) 759cirrhosis (abst) 257CRF (abst) 263

disappearance in dogs (abst) 275

down regulation of receptors (abst) 287

enalapril (abst) 1038

ESRD, periodic determinations (abst) 287gentamicin induced ARF (abst) 366GFR in hydronephrosis (abst) 358head out water immersion, cirrhotics (abst) 272hemodialysis in chronic uremic patients (abst) 758hypercalciuria (abst) 340hypervolemia in nephrotic humans (abst) 281

ligand, BP (abst) 271molecular forms in plasma and urine (abst) 201Na urinary excretion (abst) 373

• 1016290

143207

• . 281144347

• . 917

xliv Subject Index: Vol. 33

particulate guanylate cyclase activity (abst) 266relaxation of mesangial cell (abst) 285release during chronic Na loading (abst) 265renal effects of infusion (abst) 258renin-angiotensin system regulates (abst) 286sequential studies in baboons (abst) 140SIADH (abst) 192

superficial proximal tubule (abst) 289thyroid hormone status (abst) 290type 1 diabetes (abst) 270varying chronic Na intakes (abst) 285vasoconstriction in hydronephrotic (abst) 273vasporessin and renal nerves (abst) 26622Na uptake 291ligand, BP (abst) 271

Atriopeptin IllcGMP, renin (abst) 267hemodynamics and natriuresis (abst) 284

Autoantibodyanti-granulocyte cytoplasmic (abst) 329crescentic GN (abst) 313germline V gene utilization (abst) 325

Autoantigen GP600, HN (abst) 160Automated CAVED (abst) 223Autoradiography, calcitonin (abst) 138

Avidin A, proteinuria (abst) 313Axonal conduction, neuron disease (abst) 625Azotemia

anemic, hematocrit (abst) 184dehydration, urea (abst) 391endotoxin-injected conventional rats (abst) 375high flux dialysis, rHuEPO (abst) 239vitamin B6 deficiency (abst) 388

B cell function in uremics (abst) 185B-endorphin in HD (abst) 221Bacteriuria and diaphragm use (abst) 132Band 3 anion exchanger (abst) 168Barium, K transport (abst) 420Baroreflex sensitivity and sex (abst) 411Bartter' s syndrome

hyperaldosteronism and nephrocalcinosis (abst) 146Basal membranes

structural heterogeneity, IMCD (abst) 432Basolateral membrane

ATP, ADP and AMP inhibition of cation channel(abst) 428

cellular heterogeneity (abst) 430dopamine receptors (abst) 433identification of C1HC03 in IC (abst) 408K channels (abst) 424measurement of potential (abst) 420vesicles, ionic mechanism of Na HCO3 (abst) 407

Bence Jones proteinuriaplasma exchange in ARF due to multiple myeloma. . . 1175

Benzoate, Gln ammoniagenesis (abst) 392Benzodiazepines, transport (abst) 431Beta

blockade, hypertension (abst)carboline and salt, BP (abst)endorphin, reabsorption (abst)receptor, cAMP (abst)subunit of renal Na-K ATPase (abst)

Beta-adrenergicreceptors (abst)stimulation, cAMP (abst)

Beta-l adrenergicantagonist, dialysis (abst) 182

Beta-2-microglobulinallograft inflammatory cells (abst) 442amyloid deposits, chronic HD (abst) 242before and after HD (abst) 760circulating form in dialysis (abst) 332early detection of renal damage in children (abst) 137hemodialysis associated amyloid protein 24:S-30high flux HD (abst) 234in hemodialysis (abst) 755pitfalls in interpretation of changes, HD (abst) 225removal during dialysis (abst) 217skeletal lesions, amyloidosis (abst) 756synthesis in dialysis (abst) 228

Betaine synthesis, TM (abst) 433Bicarbonate

absorption by peptide hormones (abst) 400All, early proximal acidification (abst) 398electroneutral secretion, Cl transport (abst) 403flow rate determines reabsorption (abst) 404kinetics during biofiltration 24:S-120pKa in evaluating dialysate (abst) 623PTH analog inhibits action on HCO3 (abst) 341reabsorption in chronic metabolic acidosis (abst) 404reabsorption to feeding and NaHCO1 gavage (abst). . . . 404regulation of pH in PCT (abst) 403secretion (abst) 402transport in CT (abst) 387

Binding sites for PTH (abst) 338Biocompatibility

granulocyte adherence changes 24:S-68Biofiltration

uremia 24:S-14lBiopsy

anemia a risk factor in (abst) 202comparison in allograft recipients (abst) 440in children (abst) 142

steroid pattern (abst) 207Bladder

osmotic H20 permeability, membrane fluidity (abst) . . . 164Blood

adenosine on renal function (abst) 276autoregulation of flow and GFR (abst) 414azotemic anemic patients, hematocrit 184cooling during dialysis (abst) 221erythropoiesis and erythropoietin levels (abst) 372flow dynamic and UF kinetics in CAVH (abst) 236ionized Ca on systemic arterial pressure (abst) 295membrane interaction in HD (abst) 216mononuclear cells, immunoglobulin production

(abst)mononuclear cells, verapamil (abst)recirculation and effective clearances (abst)release of eicosanoids, dialyzer membranesrheology in IgA nephropathy (abst)transfusions in transplants critical (abst)uremic factor in ATPase (abst)uremic plasma on RBC insulin receptorvasa recta flow in ARF (abst)

297308275258156

318455219

24:S-82134455222378369191volume difference in hematuria (abst)

Blood pressureACE and Ca inhibitors, renal injury (abst) 129

276 and vasopressin changes in hypertension (abst) 294172 extracellular Ca2 modulates Vmc (abst) 304

Subject Index: Vol. 33 xlv

indirect ambulatory monitoring, hypertension (abst) . . . 308instruments for clinical research evaluated (abst) 145K depletion causes Na retention (abst) 299macronutrients (abst) 309nonvasorelaxant atrial peptide ligand (abst) 271portprandial changes during RD (abst) 238PTH level, in humans (abst) 308renorenal reflexes in SHR (abst) 299stress salt (abst) 308

Body mass index, excretion (abst) 383Bombesin, AYP action (abst) 282Bone

Al load and histological disease, HF and HD . . . . 24:S-168desferrioxamine, PTH (abst) 221disease in children on CAPD or CCPD 975disease in dialysis patients (abst) 337extrarenal complications of NS 1184forearm bone mineral content in dialysis (abst) 349formation rate in uremia (abst) 628lead in dialysis patients 601mineral content in transplanted patients (abst) 756preventing disease, CaCo3 and vitamin D3 24:S-178RAS oncogene transformed NIH3T3 cells (abst) 349remodeling, WR-2721 934turnover and 1 ,25-dihydroxycholecalciferol, K

binders 989Bowel pathology, CAPD peritonitis (abst) 133Bradykinin

EGF, cell proliferation (abst) 168hydronephrotic kidney sensitivity to 71PGE2 synthesis and Ca2 in arterioles (abst) 261

Brainmaturation in chilren with NS (abst) 182sex difference in Na transport (abst) 191

Branched-chain amino acidshemodynamics 91

Brush borderarginyl and histidyl groups, anion exchange (abst) 438fluorescence studies, gentamicin (abst) 360Na!H exchange in BBMV (abst) 430phosphonoformic acid binding protein from (abst) 160purification of protein from (abst) 398trypsin (abst) 408

Bubble cell (abst) 198Bumetanide

alkalosis impairs response to (abst) 200Butanol permeability, ADH (abst) 434

Caffeine, papillary damage (abst)Calcitonin

receptors (abst)release during HD inappropriate (abst)..salmon in human (abst)

Calcitiiolbioavailability (abst)clearance in ARFdeficiency in CRFhyperparathyroidism in CRF (abst)plasma kinetics, serum PTH (abst)status changes in hypertension (abst) .synthesis decreased in SHR (abst)women with osteoporosis (abst)

Calciumabsorption by amiloride (abst)absorption, Ca-ATPase (abst)absorption, thiazides stimulate

absorption, verapamil (abst) 343age-associated reduction in cytosolic (abst) 338alkalosis (abst) 338and K channels, cultured mesangial cells (abst) 164anoxia (abst) 359antagonists and CsA (abst) 454AVP sensitive cAMP metabolism by (abst) 268blood ionized, systemic arterial pressure (abst) 295calcitriol deficiency in CRF 722cAMP as second messengers for vasopressin (abst). . . . 286cAMP effect on Na transport (abst) 422carbonate, phosphate binder 24:S-l84cerebrospinal fluid, CSF Ca2 (abst) 297channel blockade (abst) 298channel blockade, PAF (abst) 413channel blockers, capillary pressure (abst) 370channels in basolateral membranes of PTC (abst) 171

chlorothiazide, furosemide, bumetanide (abst) 339chlorthalidone promotes mineral retention,

hypercalciuria 1140compartmentation during anoxia (abst) 361CsA uptake inhibited (abst) 451CsA on signalling and PGE production (abst) 361cytoplasmic inhibitor (abst) 622cytosolic free, diet and changes in medium (abst) 350cytosolic response to vasopressin in LLC-PK1

(abst) 289cytosolic, parathyroid cells, vitamin D3 850cytosolic, vitamin D3 (abst) 349dependency of hypotonic volume regulation (abst) . . . . 436dietary vs. supplemental, BP (abst) 302effects on Na flux (abst) 421epinephrine, PGE2 in MCT; Ni and AVP production

(abst) 287extracellular modulates Vmc (abst) 304fibroblast 4SCa washout (abst) 303free cytosolic in platelets (abst) 300free cytosolic, kidney growth (abst) 391free cytosolic, lymphocytes of SHR (abst) 292FURA 2 measuring (abst) 166hormones affection excretion (abst) 140

hypertension (abst) 300impaired efflux in SHR (abst) 300increases Na transport (abst) 423K and vitamin D in essential hypertension (abst) 627measurement of ionized (abst) 351

messenger system activation, PTH (abst) 340metabolic acidosis (abst) 351Mg flux and NaC1 (abst) 348mobilization by protein kinase C (abst) 277

138 overload differs from cell injury (abst) 359232 oxalate crystal binding in PCT (abst) 170350 oxalate effect on mitochondria (abst) 174

250oxytocin receptors in LLC-PKI cells (abst) 173

530 PGE induced elevation in MDCK cells (abst) 148

722 platelet cytosolic in essential hypertension (abst) 303

755 PTH-independent Pi uptake (abst) 348PTH, vitamin D3 in CRF 1049

294 set point, Al, dialysis (abst) 231

304 uptake by microsomes, maleate (abst) 165

345 urinary inhibitors modulated by 1005vitamin D, SHR (abst) 291

341 vitamin D3 in hypercalciuria (abst) 336347 vitamin D3, SHR (abst) 305

voltage sensitive channels (abst) 158

135

954

xlvi Subject Index: Vol. 33

voltage-gated currents in adrenal cells (abst) 29128K binding protein, localization (abst) 335

Calcium citratephosphate-binding agent for treatment of CRF 95

cAMPacetate (abst) 219apical membrane amplification (abst) 427beta-adrenergic stimulation (abst) 172beta-receptor mediated regulation (abst) 258catabolism, diabetes insipidus (abst) 264Ca2 signaling systems in UMR-106 cells (abst) 271demeclocycline, vasopressin (abst) 252independent of prostacyclin production (abst) 271pertussis toxin, somatostatin inhibition 536pH, and cell to cell communication (abst) 164regulates Cl conductance (abst) 421

Cancernephrocalcin in urine (abst) 209

Candida peritonitis, tuftsin (abst) 244CAPD

aceptic peritonitis (abst) 142bioavailability of calcitriol (abst) 250bone disease in children on, CCPD 975compared to HD 24:S-l23cortisol and corticosteroid binding (abst) 251

diabetic, intraperitonal insulin (abst) 246effluent, immunologic assessment (abst) 244exit site infections, catheter manipulation (abst) 243gram negative infections (abst) 249imipenem in treatment of (abst) 759long term effects, carbohydrate and lipid (abst) 1036long term experience with diabetes (abst) 251

lympho-monokine abnormalities (abst) 627"0" set (abst) 245

pediatric, lipoproteins in (abst) 248performed by relatives (abst) 759peritoneal transport of proteins, dextrans (abst) 1038

peritonitis (abst) 133peritonitis assiciated with bowel (abst) 133peritonitis in HIV infected (abst) 245peritonitis, IP vancomycin therapy (abst) 136

plasticizers exposure, membrane (abst) 246progressive decrease of serum albumin (abst) 757

teaching hospital experience (abst) 142

trimethoprim sulfamethoxazole prophylaxis (abst) 244ultrafiltration lower in children (abst) 247vancomycin superior to cefazolin in peritonitis

(abst) 245

Captoprildiltiazem in adriamycin nephropathy (abst) 382hypertension, renal arter stenosis, RDS (abst) 292iloprost and OKY 046, renal failure (abst) 281in normal subjects (abst) 282measurement of renin in hypertension (abst) 261NaCl reverses renal failure (abst) 364PG blockade in denervated kidneys (abst) 277

post-transplant hypertension (abst) 441renal plasma flow predicts response in HT (abst) 294reversible renal failure (abst) 254test for renovascular hypertension (abst) 296

Carbachol, phosphoinoside (abst) 165Carbicarb in acidosis (abst) 407Carbohydrate, proteinuria (abst) 326Carbonic anydrase staining, new (abst) 399

CardiacANP role, anti-ANP antibody (abst)choice of ESRD treatment according to status

253

of 24:S-l91compliance in myocardial interstitial fibrosis,

uremia 804CsA effect on relaxation of artery (abst) 274

Cardiopulmonary arrest, acid-base (abst) 185Cardiovascular

changes during sleep, ESRD (abst) 628Carnitine

levels, esters in CRF (abst) 213Castration prolongs life, CRF (abst) 373Catecholamine

receptor binding in kidney, aging 1073Catheter

compare 2 in peritoneal dialysis (abst) 250exit site infections in CAPD (abst) 243internal jugular (abst) 218silicone, Dacron cuff (abst) 231subclavian, long-term dialysis (abst) 231tunnel infections reduced (abst) 245

CationATP, ADP and AMP inhibiton in BLM (abst) 428organic transport (abst) 436

CAVHblood flow dynamic and UF kinetics (abst) 236hemodynamics in (abst) 229in vitro simulation and math model 685postdilution vs. predilution (abst) 228report of 100 patients (abst) 757

CAVHDautomated (abst)effecient renal replacement therapy (abst)treatment for newborns with ARF (abst) .

CCK-8, cation transport (abst)cDNA ACE isolation (abst)CD4+ specific suppressor cell (abst)Cell

223233226138150443

ADH regulates volume (abst) 427anatomy of renin-secreting, APKD 1084bubble (abst) 198division, organelle inheritance (abst) 149EGF stimulates mitogenesis in medullary (abst) 255electrophysiological identification of, in CCT (abst).. .. 397epithelial, mesangial and endothelial lines 677functional heterogeneity in CCT (abst) 430isolation of principal and intercalated (abst) 155PHi determination in proximal tubular (abst) 163red production, anemia of ESRD 983red, serum folate levels in dialysis (abst) 756regulatory volume decrease in CCT (abst) 439rubidium uptake 642suppressor induction and inducer lymphokine (abst). . . 451swelling, propionate (abst) 418T suppressor inducer (abst) 450volume regulation in PT (abst) 428

Central pontine myelinolysis (abst) 204Cephalosporin

antibiotics (abst) 368aminoglycoside toxicity 900corrects phagocytic deficiency in HD (abst) 236, 1035protein binding (abst) 247

Cerebrospinal fluid, ANF (abst) 256

Subject Index: Vol. 33 xlvii

cGMPsecond messenger of adenosine, renin release 798

Channelsingle, PT (abst) 425

Childrenaccelerated growth following growth hormone (abst). . . 190ARC/AIDS and NS (abst) 210bone disease, CAPD or CCPD 975CsA induced remission of NS 729CSA, nephrotoxicity (abst) 214cytomegalovirus pneumonia (abst) 223early detection of renal damage (abst) 1378glomerular adaptation after nephrectomy in infants

(abst) 409growth hormone in uremics 45hearing loss in dialysis (abst) 249HUS favorable outcome (abst) 203hypercalciuria in hematuria (abst) 210IgG subclass depression, NS (abst) 333Jordanian, hypertension (abst) 305overview of pediatric nephrology 1016plasma infusion in HUS (abst) 206renal biopsy (abst) 142renal functional reserve in CRF (abst) 188steroid pattern to biopsy (abst) 207treatment of IgAN (abst) 181urine sediment and ARF (abst) 1041vesicoureteric reflux (abst) 179

ChlorideAll role in glomerulo-tubular balance (abst)base exchange regulates pH1 (abst)bicarbonate exchange regulates pH (abst)cAMP regulates conductance of (abst)channel activation, Ca signalling (abst)channel blocker, transport (abst)conductance defect, dialysis (abst)deplete in chronic metabolic acidosis (abst)depletion in K-Cl depletion alkalosis (abst)during euglycemic insulin antidiuresis (abst)extracellular ion concentration, 1P3, PGE2, Ca

(abst)fetal calf serum stimulates conductance (abst)K channel currents in BLM (abst)modulation of channel blocker effect (abst)reversible Cl dependent K flux (abst)transport in BLMV (abst)transport, electroneutral HCO3 secretion (abst)voltage dependant channel (abst)

Chlorophenylthio-cyclic AMP (abst)Chlorothiazide and GFR (abst)Chlorthialidone, hypercalciuria 1140Cholecystokinin and VIP (abst) 288

CholestryamineLDL catabolism (abst) 384

resin, PAN (abst) 376Choline dehydrogenase, IM (abst) 433

Chorionic gonadotropin, pregnancy (abst) 260Chronic renal failure

adrenergic receptors (abst) 295alanine flux (abst) 395

alimentary protein, K restriction (abst) 1041ANP (abst) 263atrial peptide SC-44900 effects (abst) 290Blacks on dialysis (abst) 204brain maturation in children (abst) 182

calcitriol (abst) 755calcium citrate 95calorie restriction (abst) 386cation transport in thymocytes (abst) 371

cellular cytokine generation (abst) 234creatinine deficit, toxin production (abst) 375dietary treatment, amino acids, keto acids (abst) 138

drug protein binding 996early, effect of protein (abst) 204enalapril long term (abst) 379fluid intake (abst) 381

growth, enalapril (abst) 374hair and serum Al in children (abst) 139hypermetabolism in remnant kidney (abst) 129infant nutritional management (abst) 193insulin release from pancreatic islets 1066

lisinopril (abst) 142low protein diets (abst) 376lupus nephritis, indices of outcome (abst) 331

nisoldipine (abst) 189oxydative metabolism of granulocytes (abst) 625PAN differences in rat strains 524

pericarditis 24:S-10predictors of progression (abst) 183

progression in solitary kidneys (abst) 206

proteolysis by thyroid hormone (abst) 391

pruritus (abst) 759

psychological symptoms 24:S-l8PTH and fatty acids oxidation in skeletal muscle 555PTH and vitamin D3 1049

rational therapeutic principles 116renal functional reserve in children (abst) 188

response to hANP (abst) 287

secondary hyperparathyroidism, hemodialysis 1041TCA cycle (abst) 624thromboxane synthetase antagonist ameliorates 77thyroid hormone (abst) 195

urinary abnormalities (abst) 37524-hour integrated GH determinations in children

(abst) 197Chronic renal insufficiency

carnitine levels and esters (abst) 213hyperparathyroidism in hormonal disorders (abst) 133

protein stimulation (abst) 103324,25(OH)2D3 blunts hypercalcemic effect (abst) 347

Chronic serum sickness, PGS (abst) 1037Cirrhosis

ANP infusion (abst) 257ANP role in head out water immersion (abst) 272eicosanoids in control of hemodynamics (abst) 272

primary biliary, CSA (abst) 212Clathrin coated vesicle proton pump

structure (abst) 177

17 kDa (abst) 174Clinical competence in nephrologists 608Clone

early growth response gene (abst) 175

MDCK cells with electrical resistance (abst) 406Na dependent sugar transport system (abst) 438molecular, of gene (abst) 155

sequencing of cDNA (abst) 159Cobalt

action, antidiuretic hormone (abst) 260myocardium and skeleton (abst) 152

Coccidioidomycosis, amphotericin B(abst) 193

421399403421162416379409402271

163168428422429417403422255412

xlviii Subject Index: Vol. 33

Coichicine, gentamicin in uptake (abst) 176Collagen

gel tissue culture, TIN (abst) 137trimeric type I (abst) 158

Complementactivated C3 and C5, pulmonary artery (abst) 233activation in plasma exchange (abst) 756activation, membrane proteins (abst) 323activation, polymorphonuclear leukocyte, HD (abst)... 225binding of, to membranes (abst) 218C5b-9, membranous nephropathy (abst) 331decay accelerating factor (abst) 324depletion, immune complex GN (abst) 323membrane attack complex (abst) 153streptococcal nephritogenic antigen effect (abst) 144

Conductancevesicles deliver water particles (abst) 261

Conductivity, sodium taurocholate 782Contrast dye and HD (abst) 229Contrast media-induced ARF 699Contrast nephropathy

azotemic diabetics (abst) 201in NS (abst) 180

Contrast nephrotoxicity (abst) 208Contrasuppression, aTBM (abst) 319Converting enzyme inhibition

All blockade (abst) 384protein restriction, glomerular injury (abst) 386puromycin aminonucleoside nephrosis (abst) 373

Coronary arterybypass, ESRD (abst) 225disease in allograft recipients (abst) 136

Cortical collecting ductmetabolic acidosis (abst) 406

Cortical collecting tubuledifferentiated transport functions (abst) 167electrophysiological ID of cells (abst) 397K adaptation (abst) 418volume regulatory increase (abst) 436

Cortical interstitial cellsensitivity of hydronephrotic kidney to bradykinin 71

Cotransport, glutamate/H (abst) 394Crack abuse in renal disease (abst) 181Creatininase activity in CRF (abst) 375Creatinine

fingernail (abst) 181CrEDTA/TcMDP ratio (abst) 139

Crescentic glomerulonephritisanti-granulocyte cytoplasmic autoantibody (abst) .. . 313, 329GBM necrosis and crescent organization 966

Crioglobulinemiaglomerular immune deposits in (abst) 626

Crystalscalcium oxalate in PCT (abst) 170

Culture of glomerular cells 677

Cuprophanef32M (abst) 220

Cyclooxygenasebiocompatibility of HD membranes (abst) 217inhibition (abst) 277

Cyclophosphamideprednisone, in membranous glomerulonephritis (abst) . .. 185

CyclosporineANF in nephrotoxicity (abst) 356associated chronic nephropathy (abst) 366

Ca channel blocker inhibition (abst) 451dietary protein intake affects (abst) 357dietary protein restriction, rejection (abst) 1038effect on hemodynamics (abst) 368elevated metabolites (abst) 446erythromycin (abst) 448fractional excretion of Na (abst) 451genetic susceptibility to hypertension (abst) 293ginkgolide mixture protects vs. toxicity (abst) 449glomerular lesions analyzed (abst) 448hyperchloremia, hyperkalemia (abst) 361hypotonic cell volume regulation by (abst) 368infusion rate on nephrotoxicity (abst) 442interacts with Ca antagonists (abst) 454long term course of chronic nephropathy 590low dose (abst) 445MCNS, T cell abnormality (abst) 329methylprednisolone pharmacokinetics (abst) 454nephroxicity in Sprague-Dawley (abst) 443nifedipine, propanolol (abst) 367NS in children (abst) 185on Ca signalling and PGE production (abst) 361oral bioavailability after transplant (abst) 455pediatric transplantation (abst) 445polyglobulism (abst) 452post-transplant glucose intolerance (abst) 450primary bilaiary cirrhosis (abst) 212reduces degranulation of PMN-leukocytes (abst) 455renin content, concentration in hypertension (abst).... 267single kidney and injury from (abst) 443suppressor cell induction, inducer lymphokine (abst) . . . . 451toxicity, Ca and protease restriction (abst) 359tubular function (abst) 444TxB2 (abst) 254urinary Mg wasting (abst) 451vasoconstrictor effects of norepinephrine (abst) 442verapamil interaction (abst) 449verapamil on PGE production (abst) 355vs. donor specific transfusion (abst) 444

Cyclosporine Adevelopment of immune-mediated interstitial

nephritis 1113focal GS (abst) 322heart transplant, acidification study (abst) 440hydergine (abst) 1037hyperreninemic hypoaldosteronism (abst) 274idiopathic nephrotic syndrome (abst) 1035

IgA nephropathy (abst) 131

relaxation of artery (abst) 274remission of relapsing NS in children 729renin secretion (abst) 446renin secretion in isolated JG cells 947rheumatoid arthritis (abst) 761T cell activation pathway (abst) 453

CystAPKD histochemical studies (abst) 333

cystic kidneys 610MDCK, enlargement in hydrated collagen gel (abst) ... 386reducing volume in APKD (abst) 181

screening protocol for ADPKD (abst) 191tubular origin function changes in cystic disease 8

Cystic diseasediphenylthiazole 1130

Cystic fibrosismicronephrocalcinosis (abst) 435

Subject Index: Vol. 33 xlix

Cystinuria, thiola therapy (abst) 758Cytochrome P-450 expression (abst) 162

Cytokine generation, CRF (abst) 234

Cytomegalovirusin grafts (abst) 444pneumonia, HD (abst) 223

Cytoplasmic alkalinization, GF (abst) 266Cytotoxic antibodies

HLA B + DR graft matching (abst) 133

Cytotoxins, TNF (abst) 320

Cytoxan, lupus nephritis (abst) 179C3 levels, SLE renal activity (abst) 328C3/C5 convertases, anti-FX1A (abst) 321

D-glucitol and aldose reductase role 635Dahl rat, hypertension and renal disease 1119Data base for tracking HD patients (abst) 220Decay accelerating factor (abst) 324Deferoxamine

ARF (abst) 363

mucormycosis, dialysis (abst) 238Dehydration

and azotemia (abst) 391

hypertension (abst) 307vasopressin and blood changes (abst) 141

Deoxyribonucleic acid, lupus nephritis 487Desferrioxamine

infusion test (abst) 625PTH response to Ca change in bone disease (abst) .... 345

Desmin, marker for mesangial cell (abst) 158Dexamethasone

coichicine, CPM (abst) 204heparin sulfate (abst) 161

Diabetesarachidonic acid (abst) 393azotemic, contrast nephropathy (abst) 201CAPD, intraperitoneal insulin (abst) 246

cold hemodialysis (abst) 222decrease in Na-K ATPase activity (abst) 420determination of urine albumin excretion (abst) 214enalapril, GFR and RPF (abst) 189ESRD, racial disparity in survival (abst) 187fish oil (abst) 385genetic linkage, DNA marker (abst) 1035GFR, fluid volume and ANF (abst) 268glycation of albumin 673growth factor in nephropathy (abst) 201hyperfiltrating, PGE2, GFR and albumin (abst) 199hypernatremia in women (abst) 179hypertension alters PG response to (abst) 378hypouricemia (abst) 208improved prognosis for transplantation (abst) 441intracellular Na, role of glucose 792intralysosomal proteolytic enzymes, hypertrophy

(abst) 376long term experience in CAPD (abst) 251PAH (abst) 389PGE2 production in hypertension 1100

plasma clearances (abst) 187

protein kinase during renal growth (abst) 393

proteinuria determines prognosis (abst) 197

risks of nephropthy (abst) 193role of myo-inositol (abst) 372

tubuloglomerular feedback (abst) 412

Diabetes insipidusabnormal cAMP catabolism (abst) 264

catabolism of cAMP and cGMP (abst) 267factor VIlIc, MAP, pulse and renin in (abst) 182platelet AVP as marker (abst) 180

Diabetes mellitusalpha-hAMP hemodynamics (abst) 282ANP related to blood glucose (abst) 759

carbohydrate and proteinuria (abst) 326disordered Ang II receptor regulation (abst) 302

glomerular size and charge selectivity 100

hemodynamics in childhood, insulin-dependent (abst) ... 757

microalbuminuria and GFR (abst) 189poorly controlled ANF (abst) 254role of All receptors (abst) 380

Diabetes, type 1atrial natriuretic peptide (abst) 270

Diabeticreversal of hyperfiltration (abst) 387

Diabetic nephropathyacetazolamide (abst) 209body fluid volumes, osmotic gradient (abst) 194protein and BP (abst) 190

protein restriction, lipoprotein (abst) 213renal reserve, protein restriction (abst) 184

DialysateCAVJ4D efficient (abst) 233peritoneal, volume measurements 64pKa influence in bicarbonate (abst) 623

Dialysisacetate and succinate (abst) 228acid-base status 24:S-l 17acinetobacter peritonitis (abst) 246

adequacy 24:S-92Al and Fe overload in chronic dialysis 24:S-163ARF requiring (abst) 756associated subclavian vein stenosis 1156asymptomatic patients, amyloidosis (abst) 236beta-adrenergic antagonists (abst) 182bicarbonate kinetics during biofiltration 24:S-120bone disease (abst) 337bone disease in children on CAPD or CCPD 975bone lead 601CAPD performed by relatives (abst) 759chloride conductance defect (abst) 379circulating form of /32M (abst) 332complement activation, membrane compatibility

(abst) 230computerization of REDY sorbent (abst) 238CPR attitudes (abst) 224daily, long-term clinical metabolism 24:S-137DFO test (abst) 625drainage bag size, transport 248endotoxin-like interleukin- 1 inducing activity 29ESRD choice of treatment according to cardiac

status 24:S-191familial risk of CRF in Blacks (abst) 204first use reactions 24:S-37forearm bone mineral content (abst) 349four different short techniques (abst) 236growth hormone in uremia 45hearing loss in children (abst) 249

herpes zoster (abst) 227

high flux membranes, /32M (abst) 217

high flux, azotemia and survival (abst) 239

high flux, polysulfone membrane (abst) 239HLA-antibodies removed (abst) 443

1 Subject Index: Vol. 33

hypercalcemic, PTH and bone Al levels (abst) 345hypersensitivity (abst) 224hypertonic hemodiafiltration 24:S-132indium-ill-leukocyte scan (abst) 223induced hypoxemia 24:S-57infant nutrition management (abst) 193

integrated approach to ESRD management 24:S-145intermittent ambulatory peritoneal (abst) 244intradialytic bicarbonate infusion (abst) 227long term effect of CAPD on carbohydrate, lipid

(abst) 1036low K bath (abst) 225lupus nephritis and ESRD (abst) 140membranes, lipoxygenase activity (abst) 240morbidity (abst) 625morbidity during short term (abst) 237National Cooperative Dialysis Study (abst) 227of the future 24:S-lOOpericarditis 24:S-10peritoneal catheter tunnel infections (abst) 245peritoneal transport of water, solutes and proteins

(abst) 1036phosphatidylcholine in peritoneal (abst) 247polyacrylonitrile vs. cuprammonium rayon (abst) 234polyelectrolytes as osmotic agents for 925polymorph superoxide production (abst) 248pruritus, iron deficiency (abst) 226quality of life in aged (abst) 758recirculation and effective clearances (abst) 219red cell and serum in (abst) 756Redy system (abst) 220related amyloidosis 24:S-32removal of phosphate in uremics 24:S-180renal failure, solute specific (abst) 250renal recovery and survival in ARF (abst) 238serum aluminum monitoring (abst) 218short, rapid blood flow (abst) 237somatic and psycosocial indicators (abst) 758

sorbent, Redy compute (abst) 234subclavian catheter (abst) 231

survival analysis (abst) 188survival long term (abst) 249synthesis of 2M (abst) 228TACurea and treatment schedules 24:S-105teaching hospital experience (abst) 142termination a cause of death (abst) 235transcutaneous gas monitoring (abst) 215volume and lymphatic flow in peritoneal (abst) 247water treatment (abst) 223

Wegener's granulomatosis recurs 1035Dialyzer

cuprophane, f32M (abst)cuprophane and polyacrylonitrile performancedifferent membranes, granulocyte elastasefistula recirculation (abst)high efficiency, shortens HD time (abst)high flux, specific features (abst)membrane and HD on pulmonary mechanics (abst).membranes, syndromes associated with use"0" set in CAPD (abst)on line sterile rinse of high flux (abst)release of eicosanoids from blood cellsurea and creatinine clearances (abst)

Diaphragm use and bacteriuria (abst)

Dietacute effects of meat meal on hemodynamics (abst). . . 1033age and sex, response to immune injury 561animal protein rich, kidney stone (abst) 335calorie restriction in CRF (abst) 386Ca2 in SHR (abst) 291cytosolic free Ca concentration (abst) 350different sources of protein in humans (abst) 411HD amino, keto acid levels (abst) 143intake pattern and glomerulosclerosis (abst) 385low protein, declining renal function (abst) 139PAN, proteinuria and early sclerosis (abst) 378phosphorus deprivation (abst) 337progression of early CRF (abst) 204renal response to acute protein meal (abst) 386sodium, aromatic L-amino acid decarboxylase (abst) . . 252zinc deficiency and uremia 1091

Digitalisnatriutetic factor (abst) 192receptor, stress (abst) 304

Digoxinlike material, hypertension (abst) 307

Diltiazemtransplant, CsA (abst) 446

Diphenylthiazole, cystic disease 1130Distal nephron

trichlormethiazide (abst) 426Distal tubule, ionized Ca (abst) 351Diuresis

ANF analog, plasma, cGMP levels (abst) 176osmotic, ADH inhibition (abst) 432urinary magnesium excretion (abst) 141

Diureticchlorothiazide, furosemide and bumetanide (abst) 339loop, nephrotoxic ARF (abst) 364microalbumin excretion in diabetics (abst) 192NMR imaging (abst) 435tubular site of action of (abst) 10363H-matolazone binding (abst) 415

Djenkolic acid, ARF (abst) 359DNA

glomerular deposits (abst) 316immunoadsoprtion column for removal (abst) 199linked marker for APKD (abst) 184polymerase activity, ARF (abst) 623synthesis in mesangial cell (abst) 149synthesis, thrombin (abst) 172

DOCAsalt treatment on urinary prostaglandins 930

Donationrenal reserve filtration capacity (abst) 1033

Donoradult kidney in juvenile (abst)

Dopamineexcretion, volume expansion, natriuresis (abst) .failure to induce natriuresis (abst).receptors on BLMV (abst)

Dopamine-l in hypertension (abst)..Dopaminergic stimuli on AVP (abst)Doxazosin and hemodynamics (abst)Drug protein binding, CRF

Edema, extrarenal complications, RF 1184Effusions due to decapsulation (abst) 199EGF, mitogenesis in cells (abst) 255

22024:S-5524: S-90

241235226220

24: S-49245241

24: S-82219132

757

415410433306283144996

Subject Index: Vol. 33 h

Eicosanoidcontrol of hemodynamics in cirrhosis (abst) 272production by goldfish kidney (abst) 273production, angiotensin II (abst) 257synthesis, anionic sites neutralized (abst) 282

Eicosapentaenoic acid diet, GN (abst) 285Elastase mediates injury (abst) 312Electrical property of GEC (abst) 172Electrolyte

catecholamine receptor binding 1073composition of tubular cells in gentamicin

nephrotoxicity 1107hyponatremia (abst) 186

Electrophoresisanalysis of efferent arteriole serum protein 1181

Electrophysiology of PT cells 508Enalapril

ACE inhibitor in diabetic nephropathy (abst) 178BP control, weight change in HD (abst) 299CRF (abst) 379diabetes, GFR and RPF (abst) 189growth, CRF (abst) 374HCTZ in genetically hypertensive dogs (abst) 293microalbuninuria (abst) 209Na and H20 balance in low sodium diet (abst) 292natriuresis of ANP (abst) 1038non-invasive measurement of hemodynamics of

(abst) 301protein restriction reduces albuminuria (abst) 377

End-stage renal diseaseacid-base status (abst) 246acute pancreatitis diagnosis (abst) 183ANP in 70 patients (abst) 287coronary artery bypass grafting (abst) 225current perception threshold, nerve conduction

(abst) 241daily dialysis 24:S-137dialysis related amyloidosis 24:S-32diphenylthiazole and ADPKD 1130erythropoietin (abst) 152glistening speckled appearance (abst) 197hematopoietic progenitor cell response 983heparin compared in HD and HF 890HIV staging system (abst) 242idiopathic membranous nephropathy, untreated

patients 708integrated approach to management 24:S-145intradialytic bicarbonate infusion (abst) 227lipids in diabetic and nondiabetic (abst) 216racial disparity, survival in diabetic (abst) 187

survival patterns in lupus nephritis (abst) 212teatment strategy according to cardiac status 24:S-191termination of dialysis as cause of death (abst) 235

End-stage renal failureCanadian public health (abst) 205cardiovascular changes during sleep (abst) 628comparison of membranes 24:S-44

EndocytosisNa solute cotransport (abst) 161

Endorphin, beta, reabsorption (abst) 275Endosome

Cl dependent H ATPase (abst) 159Endostreptosin in GN (abst) 180Endothelial cell

Endotoxemiabacteremia and urosepsis (abst) 212

Endotoxinazotemia and nephropathology (abst) 375myristyl acylation, IL-l precursor (abst) 151PGE2 stimulation, pertussis toxin (abst) 289

Enzymeactivity revealed by carbonic anhydrase staining

(abst) 399BBM glucose transport (abst) 431

Eocosanoidsmesangial cell injury (abst) 286

Eosinophil, allograft dysfunction (abst) 453Eosinophilia

in HD membrane related 24:S-73heparin sensitivity 24:S-84

Epidermal growth factorcAMP and vasopressin conductivity (abst) 255cytoplasmic alkalinization (abst) 266glucose-6-phosphate dehydrogenase (abst) 173hypertrophy (abst) 387PGE2 production (abst) 274

Epithelial barrier, phosphate transfer 58Epithelial cell

anti-FX1A inhibits decay of C3/C5 convertases(abst) 321

glomerular, antibodies (abst) 314glomerular visceral, heparin (abst) 309interleukin I (abst) 317

Epithelial growth factorbradykinin in proximal tubule cells (abst) 168

Epithelial polarity, ischemia (abst) 367Erythrocyte ferritin, HD (abst) 626Erythrocytes

C3b receptor in SLE (abst) 760Erythromycin

CsA simultaneously (abst) 448Erythropoiesis

deferoxamine, Al (abst) 215rHuEPO in transplant recipients (abst) 452

Erythropoietincardiac performance in HD patients (abst) 628chronic HD (abst) 218hypertensive effect (abst) 207mechanism of action (abst) 152pharmacokinetics of rHuEpo in HD (abst) 262recombinant, HD (abst) 232

Escherichia coliresistance (abst) 131

scarring (abst) 325

Essential hypertension, hemodynamics 875Ethylene oxide in HD 24:S-62Etylendioxid IgE antibodies (abst) 755Excretion

altered hemodynamics on albumin (abst) 434ammonium, proximal tubular acidosis (abst) 183extrarenal complications of nephrotic syndrome 1184magnesium, control mechanisms (abst) 140mild charge modification of albumin (abst) 433, 1039urinary angiotensin, marker of renal production

(abst) 1036urinary divalent cation, hypertension (abst) 29724-hour protein (abst) 142

Exerciseamplification by, signal of immune complexes (abst). . . 314 tolerance in HD patients (abst) 200

lii Subject Index: Vol. 33

Exogenous adenine nucleotides (abst) 355Extracapillary glomerulonephritis

factors determining outcome (abst) 1035

Fabry's disease (abst) 182Fanconi syndrome

15N glutamine metabolism (abst) 393Fatigue, HD (abst) 239Fatty acid

CRF, PTH and oxidation in skeletal muscle 555isovolumetric regulation of S2 (abst) 438macrophage chemotaxis (abst) 323omega-3 polyunsaturated (abst) 456peroxidation of polyunsaturated (abst) 624transport by BLMV (abst) 439

Fc receptor, IgG (abst) 322Fibrin

tissue factor synthesis, LPS, TNFa (abst) 327type 1 plasminogen activator inhibitor (abst) 330

FibroblastNa/H antiport, race (abst) 29745Ca washout, race (abst) 303

Fibronectinadhesive glycoproteins in mesangial cells (abst) 154glomerular cells (abst) 318HD effect on concentration (abst) 217

Fibrosismyocardial interstitial, uremia, cardiac compliance. . . . 804nephrotoxic nephritis (abst) 321non-coronary myocardial in uremics (abst) 301

Fingernail creatinine (abst) 181Fish oil

diet, PGE2, All (abst) 384GFR, PG production and serum lipids in diabetes

(abst) 385nephrotoxic serum nephritis (abst) 322

FistulaHD associated subclavian vein stenosis 1156recirculation (abst) 241

Fluiditymembrane asymmetry in MDCK cells (abst) 163

Fluorescence activated cell sort (abst) 155Fluorophore, PT vesicles (abst) 437Flurazepam (abst) 422Fluroescence, H20 permeability (abst) 435Focal glomeruloscierosis

analogy to atherosclerosis 917cyclosporine A (abst) 322during AIDS (abst) 1041treatment of hyperlipidemia reduces injury 667

Focal segmental sclerosisdifferences in PAN in rat chains 524

Free radicalpostischemic injury 843pyelonephritis (abst) 371

Fura, calcium cell permeability (abst) 166Furosemide

D-glucose transport, gentamicin (abst) 363hemodialysis (abst) 1036kinins in renin release (abst) 274oxidative metabolism and Ca2 uptake (abst) 361m-technetium-pertechnetate uptake (abst) 416

Galactose, hemodynamics (abst) 372Gamma glutamyltransferase (abst) 391

Gamma interferonLPS (abst) 316STZ (abst) 312

Gamma-G6 monoclonal antibody 543Gemfribrozil, nephrotic syndrome (abst) 192Gene

albumin transcription in liver of nephrotic rats (abst). . . . 156AVP in regulation in rat (abst) 285calcitonin release during HD (abst) 232Class II MHC expression, TIN (abst) 158cloning (abst) 155

early expression, hypertrophy or phyperplasia(abst) 168

molecular cloning of growth response (abst) 175non- H-2, murine apoferritin, ICGN (abst) 312PC-12 cells (abst) 162transcription by proximal tubule cultures, pH (abst) . . . 169variability of C4 number in nephrotic syndrome

(abst) 165Genetic marker for ADPKD (abst) 625Gentamicin

ARF, ANP protects against (abst) 366colchicine, cortical uptake (abst) 176electrolyte composition of tubular cells 1107fluorescence studies (abst) 360focus of tissue necrosis and ARF 84furosemide enhances D-glucose transport (abst) 363glomerular hemodynamics (abst) 353hypoperfusion ARF (abst) 357nephrotoxicity (abst) 355nephrotoxicity in rat neonates 36phosphatidylinositol cascade (abst) 360phospholipase C (abst) 362thyroid hormone, lysosomal volume (abst) 356x-ray imaging (abst) 355

Germline V, autoantibodies (abst) 325Ginkgolide mixture, CsA toxicity (abst) 449Globulin binding during CAPD (abst) 251Glomerular basement membrane

anti-GBM nephritis, proteinuria reduced by CsA(abst) 1039

hematuria structure (abst) 138immune complexes (abst) 314laminin heterogeneity (abst) 149metalloproteinases (abst) 310necrosis and crescent organization 966streptococcal proteinase (abst) 311

Glomerular diseasehypercholesterolemia 498vimentin filament (abst) 134

Glomerular endothelial cellDNA synthesis (abst) 149surface electrical property (abst) 172

Glomerular epithelial cellsheparan sulfate proteoglycans synthetized by (abst) ... 174membrane attack complex of complement (abst) 153

Glomerular filtration rateACE inhibition (abst) 259ANF in diabetics (abst) 268autoregulation of blood flow and (abst) 414BCAA and hemodynamics 91captopril in control of (abst) 305chlorothiazide (abst) 412contrast media-induced ARF 699handling of 99mTc-DMSA (abst) 1034

Subject Index: Vol. 33 liii

ischemic rate kidneys (abst) 1039protein intake determinant of (abst) 183recovery from partial ureteral obstruction 775theophylline in ischemic ARF 24

Glomeruliisolated for quantitation of immune deposits 89735S labelled proteoglycans (abst) 313

Glomerulonephritisextracapillary, factors determining outcome (abst). . . . 1035helix pomatia agglutinin (abst) 320IgAN, lambda light chain IgAN 584immune complex, antibodies vs. laminin etc (abst) . . . . 317immune complex, apoferritin (abst) 314immune complex, complement depletion (abst) 323immune complex, eicosapentaenoic acid diet (abst). . . . 285immune complex, proteolytic activity (abst) 326immune complex, TxA2 synthetase inhibitor (abst) . . . . 315insulin, growth factor stimulate, TGFbeta (abst) 152intraglomerular monocytes (abst) 130isolation of glomeruli for quantitation of immune

deposits 897lupus, C3 and C4 metabolism (abst) 130mononuclear phagocytes in (abst) 135New Zealand survey (abst) 133patterns associated with hepatitis B (abst) 143platelets mediate neutrophil (abst) 318polyanion neutralization (abst) 414poststreptococcal, endostreptosin testing (abst) 180predictors of outcome (abst) 143pregnancy (abst) 132procoagulant activity augmented (abst) 134procoagulant activity of macrophages (abst) 130prostaglandins production (abst) 264

Glomerulopathies, protein (abst) 200Glomeruloscierosis

cell lines from transgenic mice 677diabetes mellitus 100diet intake pattern (abst) 385hypertrophy, cell injury (abst) 374sex vulnerability (abst) 378

Glomeruluscomparison of MLM and SEM to determine size

(abst) 325fibronectin (abst) 318plasminogen activator activity 868

GlucagonPGE mediate amino-acid induced rise in hemody-

namics 1147Glucocorticoid

metabolic acidosis (abst) 397Na-K ATPase in epithelial cells (abst) 155regulate Na absorption (abst) 416

Gluconeogenic metabolism (abst) 395Glucose

control, aerobics (abst) 326intolerance and hypertension (abst) 296intolerance, hypertension relationship (abst) 298intracellular sodium in PT of diabetic 792metabolism, X-linked hypophosphatemia (abst) 388post-transplantation intolerance (abst) 450

Glutamate H cotransport (abst) 394Glutamine

interaction with glutathione in PT (abst) 390Glutathione

altered content, post-ischemia (abst) 365

free radical-mediated postischemic injury 843hypoxia, depletion of (abst) 363redox ratio, ischemia 812transferase in urine 571

Glycan-phospholipid in MS cells (abst) 175Glycerophosphorylcholine, ADH (abst) 255Glycine protects against injury (abst) 357Glycolytic metabolism (abst) 395Glycoproteins in Heymann nephritis (abst) 164Goldfish eicosanoid production (abst) 273GP 330

Heymann nephritis (abst) 310matrix receptor (abst) 165

Graftcytotoxic antibodies and HLA B-DR matching (abst) .. 133

damaged kidneys in transplantation (abst) 146rejection, T cell immunization (abst) 135vs. host disease, murine (abst) 311

Granulocyteadherence changes, biocompatibility 24:S-68elastase, different dialyzer membranes 24:S-90

Granulocytopenia during HD (abst) 222Growth

ACE inhibitor suppresses growth of cells (abst) 296kidney, free cytosolic Ca2 (abst) 391PDGF, pH and Ca (abst) 156promoting factors after nephron loss (abst) 392renal, protein phosphorylation (abst) 159

Growth factordiabetic nephropathy (abst) 201EGF and platelet derived GF, prostanoid synthesis

(abst) 162epidermal excretion and dietary protein (abst) 376G proteins, thrombin and (abst) 160gene encoding in cisplatin nephrotoxicity (abst) 365human B cell (abst) 448platelet-derived, regulated by thrombin (abst) 148

Growth hormoneaccelerated growth following (abst) 190IGF-l, renal functin after GH injection (abst) 205in children with CRF (abst) 197Na retention (abst) 256phosphate reabsorption (abst) 344uremia 45

Growth inhibitor, crystal (abst) 340Gs alpha mutations (abst) 166GTP-binding proteins of PTH (abst) 344

H-ATPasemetabolic acidosis (abst) 404vanadate (abst) 394

HATPase, cloning and cDNA (abst) 159Habu snake venom, sulindac (abst) 310Hantavirus nephropathy (abst) 356Heart failure

ANF (abst) 262ANF in rats with high output 656ANF prevents sodium retention (abst) 272AVP gene expression in congestive (abst) 270role of renal nerves (abst) 418

Helix pomatia agglutinin (abst) 320Hematocrit

azotemic anemic patients (abst) 184blood viscosity in azotemic patients (abst) 184dietary Ca and Fe interaction, SHR (abst) 302

liv Subject Index: Vol. 33

Hematuriahypercalciuria in childhood (abst) 210neoplasia (abst) 187overview of pediatric nephropathology 1016RBC volume difference (abst) 191

thin membrane nephropathy (abst) 137Hemodiafiltration

AN 69 membrane 24:S-135biofiltration in uremia 24:S-141

Hemodialysisacquired cystic disease, adenocarcinoma (abst) 1040adequacy 24:S-92altered interleukin-1 (abst) 216associated amyloidosis (abst) 231associated subclavian vein stenosis 1156automated CAVHD (abst) 223

B-endophin levels (abst) 221blood cooling, neutrophils (abst) 221blood/membrane interaction (abst) 216bone lead 601/32—microglobulin in group (abst) 755/32M amyloid deposits (abst) 242

132M associated with amyloid protein in HD 24:S-30132M before and after (abst) 760f32M during high flux (abst) 234

capsulo synovial and bone amyloidosis 24:S-35cardiovascular instability 24: s-i 86changes in cardiac performances, rHuEPO (abst) 628

chronic, HIV testing in (abst) 235cold, in diabetics (abst) 222compared to CAPD 24:S-123complement receptors on neutrophils, monocytes

(abst) 222continuous arteriovenous 24:S-159contrast dye (abst) 229correction of anemia (abst) 189, 204correction of coagulation disturbances (abst) 622correction of phagocytic deficiency (abst) 236CPR attitudes (abst) 224cuprophane and polyacrylonitrile performance .... 24:S-55data base system (abst) 220dialyzer urea and creatinine clearances (abst) 219

down-regulation of neutrophils (abst) 241

enalapril, BP and weight change (abst) 299endotoxin-like interleukin- 1, in vitro dialysis 29erythrocyte ferritin (abst) 626erythropoietin treatment, exercise (abst) 200ethylene oxide and hypersensitivity reactions 24:S-62exercise capacity indreases, anemia correction

(abst) 206first use reactions 24:S-37four short dialysis techniques (abst) 236furosemide (abst) 1036GLA protein and bone films (abst) 232

glistening speckled appearance (abst) 197

granulocyte adherence changes 24:S-68heparin effects on plasma GH (abst) 626high flux dialyzers (abst) 226H1V infection transmission (abst) 233HIV infections (abst) 230

interleukin hypothesis 24:S-27interleukin-1 relevance to 24:S-21low molecular weight heparin 890measurement of thermal energy balance (abst) 235

membrane biocompatibility (abst) 217

membranes compared 24:S-44morbidity (abst) 625morbidity during short term (abst) 237muscle high energy metabolites (abst) 240muscle metabolism (abst) 239National Cooperative Dialysis Study (abst) 227neutrophil migration 24:S-86on-line sterile rinse of high flux (abst) 241optimum nutritional treatment, amino, keto levels

(abst) 143

oxalate appearance (abst) 198phagocytic deficiency, cephalosporin (abst) 1035pharmacokinetics of rHuEpo (abst) 262pitfalls in interpretating p2M concentrations (abst) . . . . 225plasma fibronectin (abst) 217

platelet angiotensin II receptors (abst) 230platelet lipoxygenase stimulation 24:S-80plethysmography (abst) 228poison treatment 735polyamide hemofilter (abst) 237polymorphonuclear leukocyte function (abst) 225postprandial BP during (abst) 238PTH and ionized Ca (abst) 337PTH, erythropoietin (abst) 224quality of life, r-EPO (abst) 242r-.HuEPO (abst) 218recombinant erythropoeitin (abst) 232, 240rHuEPO and anemia 623secondary hyperparathyroidism, CRF (abst) 1041

shortened time using high efficiency dialyzer (abst). . . . 235silicone catheter, Dacron cuff (abst) 231somatic and psychosocial indicators in chronic (abst) . . 758successful outcome of pregnancies (abst) 132

technetium-thallium subtraction scanning (abst) 1041technique and survival (abst) 249thymosin, anti-influenza antibody (abst) 208tumor necrosis factor, 11-1 (abst) 229urea kinetic modelling (abst) 216urea kinetics (abst) 239

Hemodynamicsacute effects of meat meal (abst) 1033All and PGI (abst) 413alpha-hANP in diabetes mellitus (abst) 282and amino acids 91anemia treatment (abst) 232antibody induced mesangial cell lysis (abst) 327atriopeptin III (abst) 284Ca channel blockade vs. Ca variation (abst) 298captopril and CyA in diabetes (abst) 193

captopril in normal patients (abst) 282

catecholamine receptor binding in kidney 1073

CAVH (abst) 229

central alpha 2 receptor (abst) 298

cyclosporine (abst) 368efferent arteriole serum protein, electrophoresis 1181

galactose (abst) 372

gentamicin (abst) 353glucagon and prostaglandins mediate amino acid rise

in 1147insulin-dependent diabetes mellitus (abst) 757irradiation of ureteral obstruction (abst) 358math model of tubuloglomerular feedback (abst) 412natriuresis of essential hypertension 875non-invasive measurement of enalapril (abst) 301

nonsteroidal antiinflammatory drugs (abst) 178

Subject Index: Vol. 33 lv

PAN and proteinuria (abst) 410paradoxical effects of insulin (abst) 410passive Heymann nephritis, C5A (abst) 755prednisolone increases glomerular permeability 1169pylonephritic renal scarring (abst) 195theophylline prevents hypoxemia-induced changes ... 1078vasopressin and oxytocin binding sites 959

HemofiltrationAl load and histological bone disease 24:S-168AN69S membrane 24:S-150in vitro simulation and math model 685low molecular weight hepann 890postdilution vs. predilution in CAVH (abst) 228protein loss during 24:S-114pump assisted, acute uremia 24:S-154ultrafiltration-pump assisted 24:S-157

Hemolytic uremic syndromechildren, plasma infusion (abst) 206favorable outcome (abst) 203intravascular platelet activation 10710 year follow-up (abst) 1034

Hemorrhagehypotensive, ANF prevents renal dysfunction (abst)... 369pulmonary (abst) 328

Heparan sulfateproteoglycans synthetized by GEC (abst) 174

Heparinin hemodialysis/hemofiltration 890plasma GH in hemodialysis (abst) 626sensitivity to, eosinophilic patients 24:S-84visceral epithelial cell proliferation (abst) 309

Heparin sulfateincreased glomerular permeability 517

Hepatitis Bglomerulonephritis patterns (abst) 143

Herpes zoster in dialysis (abst) 227Hexose monophosphate shunt (abst) 396Heymann nephritis

albuminuria causes lysozymuria 787eicosanoid synthesis, antibody binding (abst) 251indomethacin (abst) 624ligand for autoantigen GP600 (abst) 160passive, anaphylatoxin C5A (abst) 755role of GP330 (abst) 31015-deoxyspergualin (abst) 324

Histamine, permeability (abst) 250Histones, immune complex (abst) 324History, uremia 1013HIV

antibodies in Danish dialysis patients (abst) 756associated focal, segmental sclerosis (abst) 330

HormoneADH excess, micropuncture comparison (abst) 141affecting calcium excretion (abst) 140antidiuretic, cobalt action (abst) 260control of division in proximal cells (abst) 175CRF and thyroid (abst) 195effects on NaC1 permeability (abst) 425growth, IGF-1 and function (abst) 205peptide, bicarbonate absorption (abst) 400protein-induced glomerular hyperfiltration 578PTH, vitamin D3 in CRF 1049requirements, hydrolases in PTC (abst) 170responsive glycan-phospholipid (abst) 175sex, in liver disease in ADPKD (abst) 196

thyroid, CRF (abst) 195vasoactive, dietary protein (abst) 260vasopressin and oxytocin binding sites 959

Horseradish peroxidasepermeability of mesangial cell region (abst) 174

HPLC, uremic toxin 24:S-4Human B cell growth factor (abst) 448Human immunodeficiency virus (abst) 205Hybridization, site of RAS (abst) 169Hydergine, CsA induced RF (abst) 1037Hydrogen transport in IMCD (abst) 398Hydrolases

hormonal requirements for sorting (abst) 170Hydrolysis

phosphoinositide, osmolality (abst) 392Hydronephrosis, ANP and GFR (abst) 358Hydroosmosis, AVP (abst) 390Hydroxyeicosatetraenoic acid (abst) 265Hydroxyl radical, ARF, glycerol (abst) 368Hyperaldosteronism

Bartter's syndrome (abst) 146Hypercalcemia

NaCI reabsorption (abst) 424vitamin D3 (abst) 347

HypercalciuriaANP levels in (abst) 340chlorthalidone promotes mineral retention 1140modulation by calcium of urinary inhibitors 1005vitamin D3, Ca (abst) 336

Hypercapniaenhancement of Na-H antiporter (abst) 407Na }{C03 cotransport (abst) 406

Hyperchloremia, CyA (abst) 361Hypercholesterolemia

glomerular disease pathology 498glomerular injury (abst) 377lovastatin (abst) 136

Hypercholoremic acidosisdiabetic ketoacidosis (abst) 1040

Hyperfiltrationfollowing nephrectomy in donors (abst) 761injury not occur in remnant kidney model (abst) 371protein-induced, hormones 578reversal in diabetic (abst) 387

Hyperglycemiaacidosis, glucose reabsorption (abst) 201glycation of albumin in normal and diabetic rats 673K, aldosterone (abst) 214

Hyperlipidemiaand renal injury (abst) 383extrarenal complications of NS 1184treatment reduces injury in obese rats 667

Hypermetabolismphosphate restriction in remnant kidney (abst) 129remnant kidney (abst) 129

Hypernatremiabrain and kidney inositol (abst) 435trimethylamines (abst) 194

Hyperoxaluria, transplantation (abst) 209Flyperparathyroid bone remodeling, RF 934Hyperparathyroidism

calcitriol deficiency in CRF 722hormonal disorders in CRF (abst) 133

Hyperperfusionhyperfiltration in proteinuria (abst) 212

lvi Subject Index: Vol. 33

Hyperplastic/atrophic changes in cysts 8Hypersensitivity to dialysis (abst) 224Hypertension

ACTH, renal artery pressure (abst) 430air jet stress in SHR (abst) 298alters PG response to diabetes (abst) 378ambulatory BP monitoring in diagnosis (abst) 308ANF vs. captopril (abst) 277angiotensin II dependent (abst) 382atenolol and exercise (abst) 144atherosclerosis, FSGS 917BP and vasopression (abst) 294BP, family history, Na transport (abst) 293Ca, P and vitamin D in essential (abst) 627calcitriol synthesis decreased in SHR (abst) 304calcium administration (abst) 300captopril, renal artery stenosis (abst) 292cation excretion (abst) 297cerebrospinal fluid and CSF Ca2 (abst) 297changes in calcitriol in SHR (abst) 294chronic hypernatremic dehydration (abst) 307dietary Ca and Fe interaction on hematocrit (abst) . . . . 302dietary NaCl restriction vs. diuretic therapy (abst) . . . . 292digoxin-like material levels (abst) 307diphenyithiazole, ADPKD 1130DOC-salt, nifedipine (abst) 374DOCA salt treatment on urinary prostaglandins 930dopamine 1 defect (abst) 306doxazosin and hemodynamics (abst) 144

enalapril on proteinuria (abst) 295genetic susceptibility to cyclosporine induced (abst) . . . 293genetics, enalapril and HCTZ in dogs (abst) 293hemodynamics in natriuresis of essential 875hyperinsulinemic glucose (abst) 298idiopathic membranous nephropathy, untreated 708impaired Ca efflux (abst) 300in Jordanian children (abst) 305injury, high K diet (abst) 307low sodium diet, H20 balance, enalapril (abst) 292Na-lithium counter transport (abst) 307nephrotoxic serum nephritis 53niledipine and vasoconstriction (abst) 294no true sublines of WKY rats in US (abst) 300PGE2 production in diabetic rats with 1100platelet cytosolic Ca (abst) 303post-transplant, captopril (abst) 441preceding neonatal thrombosis (abst) 145

proteinuria in IgA nephropathy 716recombinant erythropoietin (abst) 207renal disease, salt-sensitive Dahi rats 1119

renal plasma flow predicts captopril response (abst) . . . 294spontaneous, glucose intolerance (abst) 296time course of PT response to (abst) 409vascular reactivity and wall/lumen ratios (abst) 305vitamin D3 in essential (abst) 627vitamin D3, Ang 11 receptor sites (abst) 304volume and neural alterations in pre- (abst) 299

Hypertonic hemodiafiltration 24:S-132Hypertrophy

diabetic kidney, enzymes (abst) 376early gene expression (abst) 168

epidermal growth factor (abst) 387glomerular sclerosis (abst) 327sclerosis (abst) 377vasopressin (abst) 264

HyperuricemiaAPKD (abst) 211

HypervolemiaANP and response to (abst) 281

Hypoalbuminemiaextrarenal complications of NS 1184

Hypocalcemiaphosphorus handling (abst)

HyponatremiaAIDS and ARC (abst)correction of symptomatic (abst).electrolytes (abst)in women with diabetes (abst).rapid correction (abst)sexual difference in survival (abst)31P-NMR to study (abst)

Hypophosphatemiax-linked, glucose metabolism (abst) 388

Hypoproteinemiasodium excretion after salt loading (abst) 1034

Hypotensioncaptopril, GFR (abst) 305dialysis, vasopressin (abst) 222lysine vasopressin (abst) 229

Hypothyroidism, ANP (abst) 290Hypouricemia

diabetic, clinical nephropathy (abst) 208Hypovolemia

extrarenal complications of NS 1184Hypoxemia

dialysis induced 24:S-57theophylline and hemodynamics 1078

HypoxiaAng II and ARF (abst) 354glutathione depletion (ahst) 363metabolic responses of RPT, anoxia (abst) 390

Hypozincemia, zinc balance, uremia 1091

Idiopathic hypercalciuriachiorthalidone promotes mineral retention 1140

Idiopathic membranous nephropathynatural history of untreated patients 708

Idiopathic nephrotic syndromeCsA in (abst) 1035serologic tests in diagnosis (abst) 194

Idiopathic renal vasculitisrisk factors in (abst) 213spectrum and outcome (abst) 214

IgAglomerulonephritis and pregnancy (abst) 136rheumatoid factor (abst) 134serum polymeric, in mesangial IgAN (abst) 137

IgA glomerulonephritispolymorphism of immunoglobulin (abst) 330

IgA nephropathyage and disease diagnosis (abst) 196anti-endothelial cell antibodies (abst) 334blood rheology (abst) 134children (abst) 181cyslosporine A (abst) 131

immune complexes model (abst) 326interleukin-2 increased (abst) 331lambda light chain IgA production (abst) 131lambda light chain synthesis 584proteinuria 716proteinuria and prognosis (abst) 203

211186186179210180178

Subject Index: Vol. 33 lvii

cellular immunoregulation (abst) 134

Clq binding, SLE (abst) 333Imipenem in treatment of CAPD (abst) 759Immune complex

antigen binding in glomerular capillary wall (abst) 310clearance by excess antigen (abst) 320deposits, platelets, GN (abst) 318erythrocyte IC clearing mechanism (abst) 311

formation, antibody (abst) 312histones (abst) 324IgA nephropathy (abst) 326lupus erythematosus (abst) 315noncationized antibodies (abst) 315non-H-2 gene (abst) 312

Immune depositclearance (abst) 316quantified 897SP4O,40 (abst) 137

Immune response, interleukin 2 (abst) 319Immunity, mucosal (abst) 329Immunoglobulin, mononuclear cell (abst) 318Immunogold technique, hematuria (abst) 138Immunosuppression

CsA, prednisone, AZA in cadaveric transplants(abst) 440

low dose CsA (abst) 445Indians, American, MGN (abst) 195Indium-Il 1-leucocyte scan, RD (abst) 223Indomethacin

antiproteinuric effect in nephrotic (abst) 381Heymann nephritis (abst) 624permselectivity in nephrotoxic serum nephritis (abst) . . 381proliferation of mesangial cells (abst) 309

Infectiongram negative, CAPD (abst) 249interleukin-l induces natriuresis 1059

Injuryabdominal aneurysm repair (abst) 623BP treatment, ACE inhibitor or Ca inhibitor

(abst) 129Ca-induced mitochondrial (abst) 362calcium channel blockers, capillary pressure (abst). . . . 370CE! and protein restriction (abst) 386cell Ca overload (abst) 359CsA induced chronic nephropathy 590cystic kidneys 610dietary sodium restriction, diuretics (abst) 292elastase mediates glomerular (abst) 312Fc receptor for IgG (abst) 322focal and segmental GS: analogy to atherosclerosis. . . . 917free radical-mediated postischemic, glutathione 843GBM necrosis and crescent organization 966glomerular, tumor necrosis factor (abst) 311

glomerulonephritis, reactive oxygen species (abst) . . . . 130glycine protects (abst) 357hyperfiltration, remnant kidney model (abst) 371hyperlipemia (abst) 383hyperlipidemia treatment reduces 667immune, diet, age and sex affects renal response to ... 561

ischemic, PGE2 (abst) 281

K permeability precedes, by HgC12 (abst) 354oxidant stress following ischemia 812PGE2 production in diabetic rats with hypertension... 1100polyethylene glycol (abst) 364progressive GS (abst) 374

proteinuria in IgA nephropathy 716reduced nephron mass and hypercholesterolemia

(abst) 377signal transduction pathway (abst) 324single kidney and CsA damage (abst) 443tubular antigen associated renal disease (abst) 131

x-ray imaging of gentamicin injury in tubules (abst)Inner medulla

dehydration (abst) 434Inner medullary collecting duct

structural heterogeneity (abst) 432Inositol

brain and kidney during hypernatremia (abst) 435leukotriene D4 binding in mesangial cells (abst) 253MDCK cells, transport (abst) 167tris, tetrakisphosphate pathway in CT (abst) 1711,4,5-trisphosphate, Ca2 channels in PTC (abst) 171

Instruments for BP measurement (abst) 145Insulin

apical, basolateral receptors (abst) 177hypertension and sensitivity to (abst) 298paradoxical hemodynamic effects (abst) 410proteolysis (abst) 396release from pancreatic islets 1066uremic plasma on RBC, receptor (abst) 378

Insulitisanti-interleukin-2 receptor antibody (abst) 321

Interferon gamma, murine lupus (abst) 316Interleukin

hypothesis in hemodialysis 24:S-27Interleukin- 1

altered in RD (abst) 216collagen synthesis in GEC (abst) 317endotoxin-like, in vitro dialysis 29gene expression in lupus nephritis (abst) 150natriuresis in conscious rats 1059proximal tubular glucose transport (abst) 319relevance in HD patients 24:S-21signal transduction pathway (abst) 324

Interleukin-2anti-, insulitis (abst) 321chimeric toxin (abst) 319mononuclear cells, IgAN (abst) 331

Interstitial gradient, excision (abst) 437Interstitial nephritis

CsA, development of immune-mediated 1113protein overload (abst) 313

intoxication, lead (abst) 143intracerebroventricular manassantin

renal function (abst) 437iron defficiency in dialysis (abst) 226[schemia

adeno sine deaminase inhibition (abst) 367allopurinol (abst) 396altered glutathione content (abst) 365ANF and dopamine (abst) 259antioxidant therapy (abst) 353course and pathogenesis in post (abst) 369epithelial polarity (abst) 367exogenous adenine nucleotides (abst) 355Na/K ATPase activity following (abst) 358organic anions, PAH, caphalothin on GFR (abst) .... 1039oxidant stress following 812oxygen free radical (abst) 354protein restriction, reduce cell injury (abst) 352

lviii Subject Index: Vol. 33

restoratin of renal ATP (abst) 396theophylline in ischemic ARF 24transplantation in Brown Norway rats (abst) 441

Ischemic acute renal failurefurosemide (abst) 361

histopathology (abst) 366Ischemic renal failure

CsA effect on (abst) 449human ANF in dogs (abst) 363low hematocrit, splenectomy (abst) 362

Isolated perfused tubule, superperfusion 1009Isolation of glomeruli, immune deposits 897Isoreceoptor IB, Na absorption (abst) 171

Isovolumetric regulation (abst) 438

Jugular catheters (abst) 218Juxtaglomerular distal tubule

MPGN (abst) 1037

Kidneystandard nomenclature

Kidney growth, protein intake 662

Kidney, singleagenesis vs. nephrectomy (abst) 195

Kinase C and renal growth (abst) 151

Kininases, mineralocorticoid, MCD (abst) 288K9/9 antibody induces proteinuria 831

L-dopa effect, Na-K pump (abst) 259L-thyroxine, TAL (abst) 362

L-triiodothyronine, Na-H (abst) 177Lactate

metabolism by TAL (abst) 395

Lambda light chain IgA (abst) 131

Lamininheterogeneity of in GBM (abst) 149

LDL catabolism, cholestyramine (abst) 384Lead

in bone with dialysis 601increases RBC Na!Li countertransport (abst) 293intoxication (abst) 143renal function risk (abst) 190

Lectinglomerular cells, staining (abst) 159

myeloma cast nephropathy (abst) 332Lesion

analysis of, after transplantation, CsA (abst) 448

catecholamine receptor binding, aging 1073

circulating DNA and lupus nephritis 487glomerular tip in NS (abst) 145glutathione transferase in the urine 571HD associated subclavian vein stenosis 1156

hypercholesterolemia 498interstitial nephritis in PAN nephrosis 14

liver; APKD (abst) 192

skeletal caused by f32-microglobulin amyloidosis(abst) 756

Leukemianephrotic syndrome in chronic lymphocytic (abst) 207

Leukopeniaxanthine oxidase deficiency (abst) 208

LeukotrieneB4, acute nephrotoxic serum nephritis (abst) 275D4 binding (abst) 253role of protein kinase C (abst) 254

Life plan, overview Marrakech meeting 24:S-2

Life support, withdrawing (abst) 758Light chain-related disease 881

Light chainsIgAN 584plasma exchange in ARF due to multiple myeloma . . . 1175

Lindane in uremics (abst) 199

Lipiddeposition, hypercholesterolemia 498ESRD(abst) 216lipoprotein alterations in nephrotic syndrome (abst) . . . 179membrane, erythrocyte cation transport (abst) 227

Lipopolysaccharide (abst) 316

Lipoproteinin children on CAPD (abst) 248

metabolism, lovastatin therapy in hyperlipidemia 1160

Lipoxygenaseactivity in HD (abst) 240during HD 24:S-80

Lisinoprilpharmacokinetics in CRF (abst) 142

Lithiumbiphasic effect (abst) 263clearance in man and dog (abst) 1034

nephrotoxicity 145tubular site of action of diuretics (abst) 1036

vasopressin sensitive adenylate cyclase (abst) 2656 and 7, renal failure (abst) 357

Liver disease, Na taurocholate 782LLC-PK1

intracellular pH (abst) 405

Na dependent transport system (abst) 438

vasopressin (abst) 161

Lovastatinhypercholesterolemia (abst) 136

therapy in nephrotic hyperlipidemia 1160

Lupus erythematosusclearance of pathogenic immune complexes (abst) 315

Lupus glomerulonephritismetabolism of C3 and C4 (abst) 130

Lupus nephritisanti-phospholipid antibodies (abst) 328

aspirin (abst) 281circulating DNA and 487dialysis and transplantation in ESRD (abst) 140

interleukin 1 gene expression (abst) 150

intravenous pulse cytoxan (abst) 179myocardial infarcts associated with SLE (abst) 132polyreactive anti-DNA antibodies (abst) 331

prediction of outcome (abst) 331

serological changes in severe (abst) 186

survival patterns in ESRD (abst) 212Lympho-monokine abnormalities (abst) 627Lymphoid cells after dialysis membrane 24:S-53

Lysine vasopressinHD induced hypotension (abst) 229

Lysozymuriacaused by albuminuria in Heymann's nephritis 787

Macronutrients, BP (abst) 309Macrophage chemotaxis (abst) 323Macula densa

mesangial cell region permeability to HRP (abst) 174

signal, renin (abst) 256

Magnesiumcontrol mechanisms for excretion of (abst) 140

diuresis in rats (abst) 141

Subject Index: Vol. 33 lix

lithium-losing nephropathy (abst) 146plasma, conservation of during Mg deprivation

(abst) 345urinary wasting, CsA treatment (abst) 451

Magnetic resonance imagingkidney transplant dysfunction (abst) 1040

MaleateCa uptake in microsomes (abst) 165

Manassantin on renal function (abst) 437Mannitol

induced ARF (abst) 188Marrakech meeting re: renal failure 24:S-2MDCK

bradykinin Ca2 transients (abst) 153inositol transport (abst) 167membrane fluidity asymmetry (abst) 163pertussis toxin and cAMP (abst) 170PGE induced elevation in Ca2 concentration (abst)... 148

Mean arterial pressure, CAVH math model 685Medulla

electrolyte, urea and water transport (abst) 427purine nucleotide cycle (abst) 393

Medullary collecting ductacetazolamide effect on kinetics (abst) 406

MembraneAl removal, membranes compared 24:S-17lAN 69 in hemodiafiltration 24:S-135anaphylatoxins C3a and C5a adsorption (abst) 226AN69S in CAVH 24:S-150artificial, thromboxane release 24:S-75binding of complement (abst) 218compared in ESRD treatment 24:S-44complement activation and biocompatibility (abst) . . . . 230eosinophilia in HD 24:S-73GBM necrosis and crescent organization 966glomerular basement, pressor effects (abst) 295granular and basal cell, particle arrays (abst) 172luminal, water permeability (abst) 269lymphoid cells after contact with 24:S-53perfusion of human peritoneum (abst) 249peritoneal, plasticizer exposure (abst) 246peritoneal, transport properties of 24:S-107potential depolarized by Cl (abst) 168superoxide in cuprophane (abst) 224syndromes associated with use 24:S-49

Membranoproliferative glomeruloscierosisinflammation of JG distal tubule (abst) 1037

Membranous glomerulonephritis 627cyclophosphamide and prednisone (abst) 185predictors of progression (abst) 183

Membranous glomerulopathyanti-laminin autoantibodies (abst) 309

Membranous nephropathycomplement C5b-9 excretion (abst) 331heparan sulfate changes, increased glomerular

permeability 517natural history of untreated patients 708predicting renal failure (abst) 200transport of C5b-9 by GEC (abst) 319

Mercury induced MGN (abst) 309Mesangial cell

desmin as a marker (abst) 158indomethacin (abst) 309proliferation by PGE2 (abst) 276proliferation, PGE2 and matrix synthesis (abst) 268

replication, AVP (abst) 286synthesis of PAF (abst) 273relaxation of, ANP, NaNpr, cGMP (abst) 285voltage-sensitive Ca channels (abst) 158

Mesangial immunoglobulin, alcohol (abst) 385Mesangialproliferative GN

SW American Indians (abst) 195Metabolic acidosis

Ca efflux from bone (abst)glucocorticoid (abst)phosphorus deprivation (abst)vitamin D3 synthesis, Ca overload (abst)

Metabolic alkalosischloride depletion (abst)

Metabolismgluconeogenic (abst) 395glycolytic (abst) 395lactate (abst) 395pyrimidine nucleotide (abst) 390

Metalloproteinases, GBM (abst) 310Methylguanidine, ARF, CRF (abst) 371Methylprednisolone, CsA (abst) 454MHC molecules, T lymphocytes (abst) 454Microalbumin, diuretics (abst) 192Microalbuminuria

enalapril (abst) 209GFR in diabetes (abst) 189

Microcytic anemia, RBC-Al (abst) 349Micronephrocalcinosis (abst) 435Microperfusion, isolated tubule 1009Micropuncture

serial analysis of SNGFR in renal ablation 855Microscopy, glomerular size (abst) 325Mineral homeostatic system (abst) 350Mineralocorticoid

acidification defect in tubular acidosis (abst) 130effect on kininases in MCD (abst) 288escape, ANF (abst) 430

Minimal change nephrotic syndromecyclosporine (abst) 329no changes in (abst) 196

Monocarboxylates in kidney (abst) 388Monoclonal antibodies

alkaline phosphatase in kidney (abst) 176anti-DNA antibodies (abst) 323anti-OKT3, cytomegalovirus infections (abst) 444epitope specific induction of proteinuria 831intercalated cells, isolation by 543nonGBM glomerular capillary wall antigens (abst) 144SGP-l 15/107, proteinuria induced 818

Monoclonal light chain-related disease 881Mononuclear

cells, heart graft survival (abst) 445phagocytes, GN (abst) 135

Morality, withdraw life support (abst) 758Morphology

of renin synthesis (abst) 145mRNAs localize RAS (abst) 269Mucormycosis

deferoxamine therapy in dialysis (abst) 238Multiple myeloma

plasma exchange in ARF due to 1175

Muramyl-dipeptide (abst) 439Murine chronic graft disease (abst) 311Murine interstitial nephritis (abst) 158

351397335342

IX Subject Index: Vol. 33

Murine lupus nephritisinterferon-gamma (abst) 316I 5-deoxyspergualin (abst) 322

Murine placental listeriosis (abst) 447Muzolimine, K conductance (abst) 424Myelofibrosis, transplantation (abst) 447Myeloma cast nephropathy

lectin and chemical studies (abst) 332monoclonal antibodies to THP (abst) 328

Myo-inositol, diabetes (abst) 372Myocardial infarction

natriuresis (abst) 205Myocardial infarcts

associated with SLE and lupus inhibitor (abst) 132Myocardial interstitial fibrosis

experimental uremia 804Myocytes in fish, ANP secretion (abst) 253Myogenic autoregulation, TGF (abst) 412Myristyl acylation, endotoxin (abst) 151

Na-K ATPaseactivity in BB diabetic rats (abst) 420cell rubidium uptake 642glucocorticoid receptors (abst) 155mediators of response (abst) 424ontogenic increase of Na-H exchange (abst) 41502 consumption, Na concentration (abst) 426PG synthesis (abst) 417G-protein modulation (abst) 150

Na/Hantiport, MDCK cells and bradykinin (abst) 153antiporter, lysine group at amiloride binding site (abst). 401exchanger, amiloride (abst) 399

Na/Caexchange, cytosolic Ca (abst) 154

Na, K-ATPaseactivity following ischemia (abst) 358ankyrin and spectrin (abst) 167

antidigoxin antibody (abst) 383oubain, bioluminescent assay (abst) 306PGE2 inhibits in IMCD (abst) 268reversible depression by ACE (abst) 303uremia effect on red cell (abst) 387

Nandrolone decanoate in uremics (abst) 221Natriuresis

acute myocardial infarction (abst) 205ANF secretion, water drinking (abst) 258ANP infusion (abst) 258APKD (abst) 211carotid artery traction (abst) 301diuretic effects of atrial peptide SC-44900 (abst) 290dopamine fails to induce (abst) 410essential hypertension, renal hemodynamics of 875high-output heart failure 656interleukin-l induces 1059nicardipine (abst) 302normal man, oral Ca, K, NE and digoxin (abst) 301oxidized ANF-analog, diuresis (abst) 176pressure, angiotensin (abst) 411pressure, Na balance in NE hypertension (abst) 296renal denervation, PGE2 (abst) 280vasopressin and renal nerves (abst) 266volume expansion, dopamine (abst) 415

Neoplasiahematuria (abst) 187

uremia corrected by dialysis (abst) 622

Neopterin levels, allograft (abst) 453Nephrectomy

adenosine nucleotides in azotemic rabbits (abst) 382chronic renal denervation (abst) 414dietary protein (abst) 353dietary protein on DNA (abst) 380fluid intake on progression of CRF (abst) 381glomerular hyperfiltration following (abst) 761glomerular procollagen mRNA (abst) 370growth promoting factors (abst) 392infant glomerular adaptation (abst) 409procoagulant and fibrinolytic activities (abst) 384reserve filtration capacity (abst) 1033sex vulnerability in GS (abst) 378vs. agenesis (abst) 143

Nephritogenicityanti-heparin sulfate-proteoglycan antibodies (abst) 320

Nephro-thyreo-arthropathia (abst) 761Nephrocalcin

crystal aggregation, surface charge (abst) 340purification (abst) 340renal cell cardinoma (abst) 209

Nephrologists, clinical competence 608Nephron

cell rubidium uptake 642deep, more vulnerable to renal mass ablation (abst) . . . 374juxtamedullary responds to perfusion pressure (abst) .. 409

proteinuria (abst) 325

Nephropathologyoverview of pediatric 1016

Nephropathyanalgesic syndrome (abst) 136congenital magnesium and lithium losing (abst) 4±6heroin associated, transplantation (abst) 442obstructive, recovery from 775risk in diabetes (abst) 193

Nephrosisalbumin synthesis (abst) 379clotting factors in (abst) 210protein restriction, ACE (abst) 188

Nephrotic hyperlipidemialovastatin therapy 1160

Nephrotic syndeomePAN nephrosis 14

AVP volume relationships (abst) 211CsA induced remission in children 729cyclosporine in chi1dren (abst) 185extrarenal complications of 1184

gemfibrozil, hyperlipidemia (abst) 192

glomerular tip lesion (abst) 145IgG subclass depression in children (abst) 333indomethacin (abst) 381lipid and lipoprotein alterations (abst) 179lovastatin therapy in hyperlipidemia 1160

lymphocytic leukemia (abst) 207no change (abst) 196PGE2 and 6-keto-prostaglandin Fla (abst) 760phospholipids (abst) 628plasma volume and ANP (abst) 261

prednisolone increases glomerular permeability 1169

serologic tests in idiopathic (abst) 194variability of C4 gene number (abst) 165

Nephrotoxic nephritisrenal fibrosis (abst) 321

Subject Index: Vol. 33 lxi

Nephrotoxic serum nephritisindomethacin (abst) 381leukotriene B4 (abst) 275with hypertension 53

NephrotoxicityAIDS patients receiving pentamidine (abst) 198aminoglycoside 900aminoglycosides-induced in rat neonates 36contrast (abst) 208CsA in children (abst) 214CsA induced remission in children 729electrolyte composisiton of tubular cells in

gentamicin 1107genes encoding growth factors (abst) 365gentamicin cortical uptake (abst) 355HgC12, glycerol induced ARF (abst) 352infusion rate on CsA (abst) 442lithium in rabbits (abst) 145model of CsA (abst) 443reduction of CsA, 16-dimethyl prostaglandin E

(abst) 452uranyl fluoride induced (abst) 370

Nervechronic renal denervation (abst) 414conduction velocity, ESRD (abst) 241renal regulation of Na-H antiporter activity (abst) 420role in heart failure (abst) 418

Netilmicin toxicity in rat neonates 36Neuron disease, axonal conduction (abst) 625Neuropeptide Y inhibition (abst) 252Neutrophil

down regulation, HD (abst) 241migration, HD 24:S-86

New Zealand GN survey (abst) 133Nicardipine, renal effects (abst) 302Nifedipine

glomerular injury in hypertension (abst) 374propanolol, transplantation with CsA (abst) 367vasoconstriction in hypertension (abst) 294

NI}{3T3 cells, bone resorption (abst) 349Nisoldipine

progression of CRF (abst) 189Nomenclature, standard for the kidneyNorepinephrine

adrenergic receptors in CRF (abst) 295ANP reverses vasoconstriction (abst) 273brain synaptosomes in CRF, role of PTH (abst) 385CsA and vasoconstrictor effects of (abst) 442Na balance (abst) 296

Novobiocin, Na transport (abst) 416Nuclear magnetic resonance (abst) 397Nucleotide metabolism, protein (abst) 389Nutrition

urea kinetics applied to (abst) 215zinc deficiency and uremia 1091

Obstruction, ureteral, recovery of 775OKT3

rejection (abst) 327Oligonucleotide, Na-K ATPase (abst) 156Organelle, cell division (abst) 149Osmolality

hydrolysis (abst) 392luminal fluid, cytosolic Ca concentration (abst) 150

Osmolytedehydration in TM (abst) 434

levels in PCT (abst) 431Osmoregulation, sorbitol in medullary 635Osmotic agents for peritoneal dialysis 925Osteodystrophy

CrEDTA/TcMDP ratio (abst) 139vitamin D and keto acids (abst) 132

OsteomalaciaPTH on Al induced (abst) 343renal failure (abst) 187

Osteoporosiscalcitriol (abst) 345

Ouabainbioluminescent assay (abst) 306mediators of NaK ATPase response (abst) 424

Overdose, treatment of 735Oxalate

Ca dependent functions of mitochondria (abst) 174in HD (abst) 198vitamin C (abst) 382

Oxidative stress, pH, Ca2 (abst) 157Oxygen

consumption and oxidant stress, protein (abst) 381consumption by peritubular protein (abst) 423consumption, alpha-adrenergic agonist (abst) 392monocarboxylates in vivo (abst) 388

Oxygen free radicalinvolvement in decrease of ATPase activity 1038ischemia (abst) 354

Oxytocinreceptors, LLC-PK1 cell (abst) 173

vasopressin binding sites 959Ozolinone effect in dog (abst) 280

Pancreas, insulin release, CRF, PTH 1066Papillary collecting tubule

myo-inositol tris-, tetrakisphosphate pathway (abst) ... 171

osmolyte levels (abst) 431Para-aminohippuric acid, diabetes (abst) 389Paracentesis, ascitis (abst) 207Paraminohippurate

gamma glutamyltransferase ammoniagenesis (abst) . . . . 397Parathormone levels, Ca therapy (abst) 452Parathyroid

vitamin D3 on cytosolic Ca in dispersed cells 850Parathyroid glands, uremia (abst) 335Parathyroid hormone

acidification by PCT (abst) 169activation of Ca2 messenger system (abst) 341age, number of receptors (abst) 348Al activity in transplantation (abst) 346Al infusion (abst) 336alpha-hydroxylase activity (abst) 338ammoniagenesis in proximal tubule (abst) 389analog, proximal HCO3 (abst) 341Ca changes, Al bone disease after DFO (abst) 345calcitriol (abst) 339changes from ionized Ca (abst) 337CRF, fatty acids oxidation in skeletal muscle 555CRF, insulin release from pancreatic islets 1066desensitization of Ca2 response (abst) 340desferrioxamine, Al bone disease (abst) 221GTP-binding proteins (abst) 344HD, erythropoietin (abst) 224hypercalcemic dialysis, Al levels (abst) 345in uremia (abst) 219inhibits Na/H exchange (abst) 298

lxii Subject index. Vol. 33

level and BP in humans (abst) 308lymphocyte in uremics (abst) 197norepinephrine metabolism in brain (abst) 385secretion during renal failure (abst) 627skeletal response to calcemic action (abst) 341uremia, Al, Ca and change of Ca (abst) 337vitamin D3 CRF 10491-34 and 1-84 binding sites (abst) 3388-Br-cAMP effect on Ca2 (abst) 343

Particle arrays in membrane (abst) 172Particulate guanylate cyclase (abst) 266PC-12 cells, genes (abst) 162PDGF, growth, pH and Ca (abst) 156Pentamidine, nephrotoxicity (abst) 198Peptide

mitogens, regulate DNA synthesis (abst) 318mouse and bovine homology 652muramyl-dipeptide (abst) 439natriuresis after carotid artery traction (abst) 301

Perfusionpressure changes and juxtamedullary nephron (abst). . . 409nephrotoxic serum nephritis 53

Pericarditis 24:S-10Peritoneal dialysis

heteroporosity model (abst) 243phosphatidylcholine (abst) 247, 248two catheters compared (abst) 250volume effect on lymphatic flow (abst) 247volume measurements 64

Peritonitisaseptic in CAPD (abst) 142CAPD (abst) 133risk factors in CAPD (abst) 244vancomycin superior to cefazolin in CAPD (abst) 245

PermeabilityADH on butanol (abst) 434experimental models (abst) 135fluorescence measurement of transepithelial water

(abst) 435histamine and antagonists (abst) 250increase with heparan sulfate changes 517NaCI and osmotic water, vasopressin (abst) 280Osmotic water, ANF (abst) 278perfusion of human peritoneum (abst) 249water and membrane fluidity in toad bladder (abst). . . . 164water, of luminal membrane (abst) 269

Permselectivityin diabetes 100polyanion neutralization (abst) 414

Pertussis toxinblocks a2-adrenoceptor vasopressin action (abst) 264cAMP, bradykinin (abst) 170endotoxin stimulates PGE2 (abst) 289somatostatin inhibition 536vasopressin (abst) 257

pHbicarbonate secretion (abst)Ca2 in oxidative stress (abst)C1 base exchange regulates (abst)intracellular, single LLC-PKI cells (abst)luminal, and AVP effect on K secretion (abst)measurement of intracellular, K depletion (abst)Na/H antiporters regulate (abst)NH3 metabolism in LLC-PK1 cells (abst)regulation of cell (abst)

steady state intracellular (abst) 403Phi determination in cells (abst) 163Phorbol esters

contract VSMC (abst) 303Na-H antiporter (abst) 428transport (abst) 415

Phorbol myristate acetate (abst) 265acetate, A23 187 (abst) 252

PhosphateAl, ESRD 24:S-172binder, calcium carbonate 24:S-l84bone turnover, I ,25-dihydroxycholecalciferol,

binders 989calcium citrate in treatment of CRF 95depletion, measurement of intracellular pH (abst) 394depletion, taurine (abst) 432hyperfiltration, somatostatin (ahst) 279metabolic alkalosis (abst) 401Na excretion, ANP (abst) 279phosphonoformic acid inhibits (abst) 348protein restriction (abst) 351PTH-independent uptake, Ca (abst) 348reabsorption, growth hormone (abst) 344restriction, hypermetabolism in remnant kidney

(abst) 129transfer in bladder, time studies 58transport kinetics (abst) 436transport, Na and pH dependent (abst) 346uptake, sodium dependent (abst) 155vitamin D3 stimulates uptake (abst) 350zinc depletion and low diet of (abst) 342

Phosphatidyicholine synthesis (abst) 248Phosphatidylinositol cascade (abst) 360Phosphoenolpyruvate carboxykinase

localization of acidosis-induced (abst) 177Phosphoi nositide

changes, Ang II (abst) 253hydrolysis, carbachol in inner medullary CD (abst).. .. 165turnover, transduction mechanisms (abst) 153

Phospholipase A2acetate (abst) 265GTP binding protein (abst) 154

Phospholipase Cgentamicin (abst) 362MDCK cells (abst) 170

Phospholipidalterations, damage in childhood NS (abst) 628content of BBMV, Al (abst) 350

Phosphonoformic acidPi uptake (abst)solute (abst)

Phosphorusdeprivation in rabbits (abst)hypocalcemia (abst)metabolic acidosis (abst)regulates vitamin D3 (abst)

Phosphorylationrenal growth (abst) 159

PlasmaANP disappears in dogs (abst)catecholamines, RF (abst)clearances in diabetes (abst)exchange, complement activation (abst)Mg deprivation (abst)volumes, colloid osmotic gradient, diabetes (abst)

344160

337339335346

402157399405426394403394403

275410187756345194

Subject Index: Vol. 33 lxiii

Plasminogen activatoractivity 868endothelial (abst) 176inhibitor (abst) 330vasoactive (abst) 157

Plasticizers, scierosing (abst) 624Platelet activating factor

All causes formation of (abst) 278calcium channel blockade (abst) 413mesangial cell synthesis (abst) 273microcirculatory responses (abst) 260multiple signaling pathways (abst) 161

permeability to proteins (abst) 280role in endotoxemic ARF (abst) 358vascular smooth muscle cells (abst) 171

Platelet activation in HUS 107Platelet arginine vasopressin

AVP in diabetes (abst) 180Platelet derived growth factor

EGF stimulate prostanoid synthesis (abst) 162Platelets, calcium in (abst) 300Plethysmography in HD (abst) 228PMN-leukocytes, transplantation (abst) 455Poison

teatment of overdose 735uremic toxins 24:S-4

Poly-L-lysine, eicosanoid (abst) 282Polyamide hemofilter (abst) 237Polyanion, heparan sulfate 517Polyaspartic acid, gentamicin (abst) 353Polycystic kidney disease

cystic kidneys 610experimental, tubular originated renal changes 8tissue culture (abst) 191

Polyelectrolytes in peritoneal dialysis 925Polyethylene glycol, injury (abst) 364Polyglobulism and CsA (abst) 452Polymeric IgA in IgAN (abst) 137Polymorph superoxide production (abst) 248Polymorphism, IgA GN (abst) 330Polymorphonuclear granulocytes (abst) 625Polymorphonuclear leukocytes (abst) 369Polysulfone

high flux dialysis membrane (abst) 239Potassium

adaptation, aldosterone (abst) 427aldosterone and kaliuresis after loading of (abst) 1037aldosterone role in high intake (abst) 270ammonia production by PT (abst) 405

225

hyperglycemia (abst) 214hypertensive injury (abst) 307mechanism of adaptation (abst) 418mechanism of aldosterone induced increase (abst) 429multiple pathways for transport (abst) 429permeability precedes injury by HgCl2 (abst) 354

permeability, uranyl nitrate (abst) 354plasma renin activity directly related to (abst) 288reversible Cl dependent flux (abst) 429stretch-activated channels (abst) 425vaspressin enhances secretion of (abst) 426

Potential, measurement of BM (abst) 420Predictors of GN outcome (abst) 143Prednisolone

conversion to alternate day therapy (abst) 449glomerular permeability to proteins in NS 1169

PregnancyANF plasma concentrations in (abst) 140ANF, aldosterone and plasma volume (abst) 257chorionic gonadotropin (abst) 260hypertension and plasma renin activity (abst) 306IgA glomerulonephritis (abst) 136membranous glomerulonephritis (abst) 132renal functional reserve (abst) 206successful in transplant recipients (abst) 441successful outcome, hemodialysis (abst) 132Tamm-Horsfall glycoprotein excretion (abst) 203

Pressor effects on GBM (abst) 295Prevention, progression of renal disease 116Procoagulant

activity of macrophages in GN (abst) 130activity in GN (abst) 134in remnant kidney (abst) 384

Procollagen mRNA, nephrectomy (abst) 370Progressive glomeruloscierosis

chronic serum sickness (abst) 1037Progressive renal disease

rational therapeutic principles 116Progressive renal failure

new antibody-antigen system (abst) 333'251-iothalamate clearance, creatinine (abst) 190

Propionate, cell swelling (abst) 418Prostacyclin production, cAMP (abst) 271Prostaglandin

ammoniagenesis in acute respiratory alkalosis (abst)... 401ANF antagonizes release of (abs) 279blockade in denervated kidneys, captopril (abst) 277cAMP and Ca2 signaling systems (abst) 271Ca2, bradykinin in arterioles (abst) 261DOCA salt treatment on urinary 930GFR, albumin in diabetes (abst) 199glomerular production, GN (abst) 264glucagon, mediates amino acid induced rise in

hemodynamics 1147hydronephrotic kidney sensitivity to bradykinin 71hydroxyeicosatetraenoic acids (abst) 265interleukin-l induces natriuresis 1059mesangial cell proliferation, matrix synthesis (abst). . . . 268modulate mesangial cell proliferation (abst) 276Na-K ATPase activity (abst) 417PTH mediated Ca transients (abst) 351

vasopressin antagonists (abst) 251verapamil, GFR and CyA administration (abst) 355

Prostaglandin E1reversal of proteinuria (abst) 321

Prostaglandin E2cytoprotective effects of (abst) 281

epidermal growth factor mechanism (abst) 274inhibits Na-K-ATPase in IMCD (abst) 268production in diabetic rats with hypertension 1100renal denervation, natriuresis (abst) 280

bath, dialysis (abst)Cail channels in mesangial cells (abst)cell rubidium uptake indexes transport ofchannels in papillary surface epithelium (abst).C1 channel currents in BLM (abst)conductance, muzolimine (abst)depletion alkalosis, PHCO3 (abst)depletion and vasopressin (abst)depletion causes Na retention, high BP (abst)depletion, metabolic acidosis (abst)

164642424428424402431299405

lxiv Subject Index: Vol. 33

6-keto-prostaglandin Fla in NS (abst) 760Prostaglandin F2a

cytosolic pH, mesangial cells (abst) 154Protein

adriamycin nephrosis (abst) 380albumin synthesis (abst) 378alimentary, phosphorus restriction and CRF (abst) . .. 1041analysis of efferent arteriole serum, electrophoresis. .. 1181BP in diabetic nephropathy (abst) 190cell injury in ischemia (abst) 352complement, SP4O,40 in immune deposits (abst) 137

dexamethasone, heparan sulfate peoteoglycan (abst)... 161diabetic nephropathy, restriction of (abst) 184diacylglycerol, kinase C, transport of fluid and K

(abst) 272diet affects response to CyA (abst) 357diet, age, sex affects immune injury 561different sources in healthy humans (abst) 411distinct G, thrombin and growth factor (abst) 160DNA, protein synthesis after nephrectomy (abst) 380drug binding in CRF 996effect of diet on muscle protein synthesis (abst) 353glomerular disease and hypercholesterolemia 498GTP-binding, Ni, cAMP production (abst) 287induced hyperfiltration 578intake, GRF and creatinine generation (abst) 183kinase C modulates bradykinin, MDCK cells (abst).... 169kinase C, activators of (abst) 419kinase C, Ca mobilization (abst) 277kinase C, leukotrienes (abst) 254kinase C, renal growth (abst) 151

kinase C, vasopressin (abst) 153

kinase during diabetic renal growth (abst) 393kinase in glomerular eipthelial cells (abst) 170

kinase, glomerular epithelial cells (abst) 170lipoprotein abnormalities, IDD (abst) 213loss during hemofiltration 24:S-l 14low molecular weight (abst) 365low, diets and CRF (abst) 376membrane, complement activation (abst) 323mitotic response to high intake 662Na-K-ATPase activity modulated by 0-protein 150nucleotide metabolism (abst) 389oxygen consumption and oxidant stress (abst) 381PAF on glomerular permeability to (abst) 280partial sequence of ACE 652pathogenic role in systemic lupus EM (abst) 317

permeability in glomerulopathies (abst) 200phosphonoformic acid binding in BBM (abst) 160

phosphorylation during renal growth (abst) 159

PKD and diet (abst) 315prednisolone increases permeability to, NS 1169purification from BBMV (abst) 398

regulation of 02 consumption (abst) 423renal response to acute meal (abst) 386renin secretion, low protein diet (abst) 275

restriction, phosphate reabsorption (abst) 351

S and 0, clotting in nephrosis (abst) 210serum binding of cephalosporin during CAPD (abst). . . 247stimulation on renal function, CR1 (abst) 1033

urinary epidermal growth factor (abst) 376vasoactive hormones and dietary (abst) 26024-hour renal excretion (abst) 142

Proteinuriaacute All blockade (abst) 383

analgesic nephropathy (abst) 141CsA reduces in anti-GBM nephritis (abst) 1039DNA effect on glomerular deposits (abst) 316enalapril in SHR (abst) 295epitope specific induction of 831high diet carbohydrate (abst) 326hyperperfusion vs. hyperfiltration (abst) 212lgA nephropathy 716IgA nephropathy (abst) 203induction by SGP-1 15/107 818long and short looped nephrons (abst) 325overview of pediatric nephropathology 1016PAN differences in rat strains 524proteases, ON, Avidin A (abst) 313protein overload, TIN (abst) 313reversal, PGE1, iloprost and TSI (abst) 321

thromboxane synthetase antagonist 77tubulointerstitial nephrosis and aminonucleoside

nephrosis 14

type 2 diabetes and prognosis (abst) 197Proteoglycan, 35S labelled (abst) 313

Proteolysisinsulin (abst) 396thyroid hormone, CRF (abst) 391

Proteolytic activity after ICGN (abst) 326Proto-oncogene expression, ARF (abst) 152Proton

NMR imaging, diuretics (abst) 435translocating ATPase in IMCD (abst) 408

Proton pumpclathrin-coated vesicle, structure (abst) 17717 kDa subunit of CCV (abst) 174

Proximal cellshormonal control of division (abst) 175simian virus 40 (abst) 151

PTH and acidification by (abst) 169Proximal convoluted tubule

ionic ammonium exit (abst) 407ontogenic increase of Na-H exchange (abst) 415PTH and acidification by (abst) 169transepithelial Na transport (abst) 421

Proximal tubular cellsangiotensinogen production (abst) 291cAMP, pH1 and cell to cell communication (abst) 164electrophysiology and ultrastructure 508

gene transcription, pH (abst) 169GP330 a matric receptor (abst) 165

hormonal requirements for membrane sorting (abst) . . . 170light chain-related renal disease 881

loop of Henle, ANP effect (abst) 289phosphate transfer in frog bladder 58reflection coefficients (abst) 437single channel recordings (abst) 425stretch activated K channels (abst) 425time course response to hypertension (abst) 409

Pruritus in CRF (abst) 759

Psychogenic polydipsiahyponatremia correction in (abst) 186

Psychology in renal failure patients 24:S-l8Pulmonary artery, C3, C5 (abst) 233Pulmonary mechanics, HD (abst) 220

PumpCa a sytoplasmic inhibitor of Na-K (abst) 622L-dopa effect on Na-K (abst) 259

proton translocating ATPases 767

Subject Index: Vol. 33 lxv

vanadate sensitive, K proton (abst) 423Purine nucleotide cycle (abst) 393Puromycin aminonucleoside

proteinuria (abst)nephropathy, proteinuria and early sclerosis (abst)nephrosis, cholestyramine resin (abst)nephrosis,converting enzyme inhibiton (abst)nephrosis, differences in rat strains

Pyelonephritic renal scarringhypervolemia, hormones and hemodynamics (abst).... 195

Pyelonephritisfree radicals (abst)renal scarring (abst)

Pyrimidine nucleotide metabolism (abst)Pyrogens, MNC-IL-1 productionPyroglutamyl-histidine transport (abst)

Radiocephalic A-V fistulas (abst)Rapidly progressive nephritis

antibodies (abst)RDT, amyloid arthropathy (abst)Reactive oxygen species

do not mediate ischemic ARF (abst)PMN (abst)

Receptorapical and basolateral insulin (abst)beta-adrenergic, two classes of (abst).clearance, of ANF (abst)DA-1, 1251-SCH23982 (abst)down regulation of ANP (abst)

Recombinant erythropoietinabsorption of, peritoneal cavity (abst)HD (abst)quality of life in chronic HD (abst)urea kinetics (abst)

Redycompute, dialysis (abst) 234sorbent dialysis (abst) 238system of dialysis (abst) 220

Rejectionanti-T cell therapy (abst) 447lymphocyte recognition of HLA-A2 (abst) 446OKT3 (abst) 327triple drug therapy in children (abst) 447

Renal ablationSNGFR, micropuncture 855steroids (abst) 377

Renal artery pressurecontrol during hypertension (abst) 430ACE inhibition (abst) 1038ACE inhibition eliminates hippuran (abst) 760

Renal decapsulationabdomen and perinephric effusions (abst) 199

Renal diseasecrack abuse in (abst) 181development of hypertension in salt-sensitive DahI . . . 1119molecular forms of ANP in plasma and urine (abst) . . . 201

Renal failureangioplasty in elderly patients (abst) 203calcitriol deficiency 722captopril, iloprost and OKY 046 (abst) 281chronic ON, severe proteinuria and TIN predict 14contrast media-induced 699contrast nephropathy (abst) 180insulin release from pancreatic islets 1066lithium 6 and 7 (abst) 357

Saline expanded dogs, ANF (abst)Saralasin

cyclooxygenase inhibition (abst)Scarring

escherichia coli (abst)hemodynamics (abst)

Sclerosis

202187

24:S-18410200627198254

hyperfiltration, perfusion, hypertension (abst) 377hypertrophy (abst) 327

plasticizers (abst) 624

761

177276279419287

243240242242

liver transplant patients (abst)osteomalacia due to interstitial nephritis (abst)perception of psychological symptoms

410 plasma catecholamines (abst)379 predicting in membranous nephropathy (abst)376 PTH secretion (abst)373 rapid in AIDS nephropathy (abst)524 reversible, captopril (abst)

skeletal response to PTH (abst) 341solute specific dialysis (abst) 250WR-272l protects against 934

371 Renal function759 decline, diet (abst) 139390 reserve, pregnancy (abst) 206

29 risk of lead workers (abst) 190438 Renal papillary necrosis (abst) 367

Renal pelvis, urea flux (abst) 439Renal plasma flow

BCAA and hemodynamics 91Renal stone disease

Saudi Arabia (abst) 213Renin

acute inhibition of converting enzyme (abst) 757anatomy of secreting cell in AKPKD 1084

angiotensinogen, gene expression (abst) 163atriopeptin III, cGMP (abst) 267cGMP a second messenger of adenosine in inhibition .. . 798CsA effect on release (abst) 274CsA enhances secretion of (abst) 446cyclosporine A hypertension (abst) 267direct measurement in hypertension (abst) 261directly related to dietary K (abst) 288kinins mediate furosemide induced release (abst) 274low protein diet (abst) 275macula densa signal (abst) 256morphological events (abst) 145secretion and production of, isolated JG cells 947selective breeding for response in low Na diet (abst). . . 278serial plasma activity, pregnancy (abst) 306

Renin-angiotensin systemANP (abst) 286asymmetric reduction of Ang II receptor sites (abst). . . 304localization by hybridization of mRNAs (abst) 269saline loading on uranium-induced ARF 942diphenylthiazole develops renal cystic disease 1130

Renoprival nephropathy (abst) 384Renorenal reflexes, SHR (abst) 299Respiration

mitochondrial, cobalt distribution (abst) 152Rheumatoid arthritis

CsA dosage in (abst) 761Rheumatoid factor in IgAN (abst) 134rHuEPO, coagulation disturbances 622Ribonucleic acid, androgen (abst) 262Rubidium, cell uptake 642

266

277

325759

lxvi Subject Index: Vol. 33

thromboxane synthetase antagonist ameliorates 77Segmental glomerulosclerosis

analogy to atherosclerosis 917Serum nephritis

fish oil diet, nephrotoxicity (abst) 322Serum sickness nephritis

T-lymphocytes (abst) 314Severe lupus nephritis

serological changes (abst) 186Sex

differences in baroreflex sensitivity (abst) 411effect of diet, age, immune injury 561NaCI excretion compared in rats (abst) 429

SGP-115/107 antibody induced proteinuria 818Shunt

oxidant stress of hexose monophosphate (abst) 396Sickle cell anemia

nonsteroidal antiinflammatory drugs (abst) 178Signalingpathways in PAF (abst) 161Ca, chloride channel activation (abst) 162

Simian virus 40 (abst) 151

Single nephron GFR, micropuncture 855SK&F 101926 VI antagonist (abst) 269Skeletal muscle

CRF, PTH and fatty acids oxidation 555SLE renal activity, C3 levels (abst) 328Sodium

aldosterone on acidification (abst) 401alpha adrenergic stimulation (abst) 388ambystoma diluting segment (abst) 419ANF in regulation of excretion of (abst) 284ANP and urinary excretion in CRF (abst) 373ANP inhibits 22Na in IMCD (abst) 291aromatic L-amino acid decarboxlyase (abst) 252bicarbonate reabsorption to feeding and gavage (abst) . . . 404binding, UMR-106 cells (abst) 400concentration, Na-K ATPase 02 consumption (abst)... 426cotransport with H in BBM (abst) 178dependent uptake of Pi, phosphonoformic acid (abst) . . . 344dependent phosphate uptake (abst) 155distal acidification, acidosis (abst) 194DOCA treatment on urinary prostaglandins 930endocytosis and, cotransport in LLC-PK1 cells (abst)... 161flux, Ca (abst) 421glucocorticoid isoreceptor (abst) 170glucocorticoid isoreceptor lB (abst) 171

glucocorticoids regulate absorption (abst)growth hormone induced retention (abst)H exchange, PTH (abst)hydrogen exchange in BBMV (abst)inhibition, protein kinase C (abst)intracellular in diabetes, role of glucoseL-triiodothyronine, H exchange (abst)lithium clearance in man and dog (abst) 1034

loading in hypoproteinemia (abst) 1034loading, release of ANP (abst) 265mitotic response to high protein intake 662NaC1 reverses renal failure (abst) 364phosphate cotransport (abst) 342pump, K leak, volume regulation (abst) 418renal disease and development of hypertension, DahI

rat 1119risk of rapid treatment of hyponatremia (abst) 210selective breeding for renin response to, diet (abst). . . . 278

sensitive BP, family history of hypertension (abst) . . . . 293taurocholate in CCT 782transport by aldosterone and arginine vasotocin

(abst) 283transport in brain (abst) 191transport in uremic RBC (abst) 372tubular reabsorption, All (abst) 129

uptake, tight junction and membrane fluidity (abst).... 156varying chronic intake, ANP (abst) 285

Sodium bicarbonateexcretion of NH4HCO3 by alligator kidney (abst) 408symporter in PCT, chronic metabolic acidosis (abst)... 405

Sodium chlorideacidemia, hypertrophy (abst) 157ANF adaptation in fish (abst) 289Ca and Mg flux (abst) 348comparison of excretion in male/female rats (abst) . . . . 429hormone effects on permeability (abst) 425hypercalcemia inhibits reabsorption (abst) 424osmotic water permeabilities, vasopressin (abst) 280

Solitary kidneyCRF in (abst) 206

Somatostatinglomerular hyperfiltration, Pi (abst) 279inhibition of AVP-induced cAMP 536

Sorbinil, All receptors (abst) 380Sorbitol

aldose reductase maintain medullary intracellularmilieu 635

Splenectomy, ischemia (abst) 362Staphylococcus areus

exit site infections in CAPD (abst) 243Stenosis

transluminal angioplasty (abst) 230Steroid, ablation (abst) 377Stone

animal protein rich diet and formation of (abst) 335chlorthalidone promotes mineral retention 1140disease in Saudi Arabia (abst) 213formers, THP (abst) 342hypercalciuric, formers and vitamin D (abst) 343modulation by Ca of urinary inhibitors 1005

Streptococcal proteinase, GBM (abst) 311Stress, digitalis receptor (abst) 304Structure, kidney, standard nomenclature 1

Subclavian vein stenosis, HD 1156Subline of WKY rat (abst) 300Substrate deprivation, injury (abst) 362Sulindac

habu snake venom (abst) 310Superoxide in cuprophane membrane (abst) 224Superperfusion, isolated tubule 1009Survival

hyponatremia, sexual difference in (abst) 180Systemic lupus erythematosus

B-cell interleukin-2 (abst) 334circulating DNA 487Clq binding IgG (abst) 333C3b receptor activity (abst) 760pathogenic role of membrane protein (abst) 317

T cellactivation pathway, CsA (abst) 453antigen secreting epithelial cells (abst) 317crossmatch pretransplant (abst) 138immunization and graft rejection (abst) 135

416256298430419792177

Subject Index: Vol. 33 lxvii

increased free cytosolic Ca2 in lymphocytes (abst) . . . 292streptozotocin, gamma interferon (abst) 312vitamin D3, 112 mRNA accumulation (abst) 346

T lymphocytecellular immunoregulation, IgAN (abst) 134signal transduction (abst) 454SSN (abst) 314

T suppressor inducer cells (abst) 450TACurea, time, schedules 24:S-105Tamm-Horsfall glycoprotein

calcium stone formers (abst) 342pregnancy (abst) 203

Taurine deprivation (abst) 432TCA cycle and CRF (abst) 624Technetium-thallium scanning (abst) 1041

Terminal complement pathway (abst) 316Theophylline

hypoxemia induced renal hemodynamic changes 1078inARF 24

Thermal energy balance in HD (abst) 235Thiazides

Ca absorption 954Thick ascending limb

ammonium ion absorption (abst) 400L-thyroxine (abst) 362

Thin decending limb of Henlevunerability in isolated perfused kidney (abst) 360

Thin membrane nephropathy (abst) 137Thiola therapy, cystinuria (abst) 758Thrombin

DNA synthesis (abst) 172platelet derived growth factor regulation by (abst) 148

Thrombosishypertension in neonate (abst) 145

Thromboxanerelease, artificial membrane after blood exposure... . 24:S-75responses to angiotensin (abst) 308synthetase antagonist in progressive renal disease 77

Thromboxane A2immune complex glomerulonephritis (abst) 315

Thromboxane B2cyclosporine A (abst) 254

Thymidine incorporation and ATP (abst) 389Thymocytes, cation transport (abst) 371

Thymosinanti-influenza antibody in HD (abst) 208

Thyroid hormone, gentamicin (abst) 356

Tight junctionopening, membrane fluidity, Na uptake (abst) 156

Tissue factor synthesis (abst) 327

Toxicityamphotericin B (abst) 360CyA, Ca and protease restriction (abst) 359electrophysiology of PT cells 508gentamicin and necrosis 84low molecular weight protein (abst) 365mitochondrial, cephalosporin antibiotics (abst) 368

Toxincoagulation defects in uremia 24:S-l3extracorporeal treatment of intoxications 735uremic 24:S-4

Training, clinical competence 608

Transcutaneous gas monitoring (abst) 215

Transfusion, Tx production (abst) 258Transluminal angioplasty, HD (abst) 230

cadaver donor age and survival of graft (abst) 450cardiac, ANP response (abst) 259combined liver-kidney, oxaluria (abst) 209coronary artery disease (abst) 136CsA pharmacokinetics (abst) 445CsA, prednisone and AZA in cadaveric (abst) 440damaged kidneys in living donor (abst) 146diabetic kidney prognosis (abst) 441donor specific transfusion (abst) 258DST vs. CsA (abst) 444eterminant of graft survival (abst) 444factors influencing function (abst) 454fractional excretion of Na, effect of CsA (abst) 451glutathione transferase in urine 571

graft loss caused by cyclosporine (abst) 146heroin associated nephropathy (abst) 442HLA-A2 recognition (abst) 446in USA not fair (abst) 446long term course of CsA-associated nephropathy 590long term predictors of graft survival (abst) 448magnetic resonance imaging (abst) 1040mononuclear cells and heart graft survival (abst) 445mucosal immunity (abst) 329myelofibrosis (abst) 447omega-3 polyunsaturated fatty acids (abst) 456oral bioavailability of CsA (abst) 455parathormone levels (abst) 452pediatric, CsA converted to AZA (abst) 445

percutaneous procedures (abst) 1040

physical working capacity, uremia (abst) 758rHuEPO and erythropoiesis (abst) 452serum 11-2 activity (abst) 453successful pregnancy (abst) 441T cell crossmatch (abst) 138

triple drug therapy in pediatric (abst) 447tubular function and CsA (abst) 444

urinary antigen (abst) 440urinary calculi (abst) 336vitamin D metabolites (abst) 623

Transportactive urea, proton gradient (abst)aldosterone and ADH (abst)aldosterone and arginine vasotocin regulate Na

(abst)ambystoma PT, Cl- linked to Na (abst)amino acid (abst)amino acid uptake (abst) 417

BBM glucose (abst) 431

benzodiazepines (abst) 431bicarbonate in CT (abst) 387Ca increases Na in BBM (abst) 423

CAPD, proteins and dextrans (abst) 1038CCK-8 (abst) 138chloride, adenosine released (abst) 270Cl channel blocker (abst) 416

Transplantationadult kidney in juvenile (abst)adult liver, RF (abst)alternate day prednisone therapy (abst)anti-T cell therapy and rejection (abst).ARF after, perfused allograft (abst)Beta blockade (abst)blood transfusions critical (abst)bone mineral content (abst)Brown Norway rats (abst)

757202449447450297455756

437283

283423432

Subject Index: Vol. 33 lxiii

Plasminogen activatoractivity 868endothelial (abst) 176inhibitor (abst) 330vasoactive (abst) 157

Plasticizers, scierosing (abst) 624Platelet activating factor

All causes formation of (abst) 278calcium channel blockade (abst) 413mesangial cell synthesis (abst) 273microcirculatory responses (abst) 260multiple signaling pathways (abst) 161

permeability to proteins (abst) 280role in endotoxemic ARF (abst) 358vascular smooth muscle cells (abst) 171

Platelet activation in HUS 107Platelet arginine vasopressin

AVP in diabetes (abst) 180Platelet derived growth factor

EGF stimulate prostanoid synthesis (abst) 162Platelets, calcium in (abst) 300Plethysmography in HD (abst) 228PMN-leukocytes, transplantation (abst) 455Poison

teatment of overdose 735uremic toxins 24:S-4

Poly-L-lysine, eicosanoid (abst) 282Polyamide hemofilter (abst) 237Polyanion, heparan sulfate 517Polyaspartic acid, gentamicin (abst) 353Polycystic kidney disease

cystic kidneys 610experimental, tubular originated renal changes 8tissue culture (abst) 191

Polyelectrolytes in peritoneal dialysis 925Polyethylene glycol, injury (abst) 364Polyglobulism and CsA (abst) 452Polymeric IgA in IgAN (abst) 137Polymorph superoxide production (abst) 248Polymorphism, IgA GN (abst) 330Polymorphonuclear granulocytes (abst) 625Polymorphonuclear leukocytes (abst) 369Polysulfone

high flux dialysis membrane (abst) 239Potassium

adaptation, aldosterone (abst) 427aldosterone and kaliuresis after loading of (abst) 1037aldosterone role in high intake (abst) 270ammonia production by PT (abst) 405

225

hyperglycemia (abst) 214hypertensive injury (abst) 307mechanism of adaptation (abst) 418mechanism of aldosterone induced increase (abst) 429multiple pathways for transport (abst) 429permeability precedes injury by HgCl2 (abst) 354

permeability, uranyl nitrate (abst) 354plasma renin activity directly related to (abst) 288reversible Cl dependent flux (abst) 429stretch-activated channels (abst) 425vaspressin enhances secretion of (abst) 426

Potential, measurement of BM (abst) 420Predictors of GN outcome (abst) 143Prednisolone

conversion to alternate day therapy (abst) 449glomerular permeability to proteins in NS 1169

PregnancyANF plasma concentrations in (abst) 140ANF, aldosterone and plasma volume (abst) 257chorionic gonadotropin (abst) 260hypertension and plasma renin activity (abst) 306IgA glomerulonephritis (abst) 136

membranous glomerulonephritis (abst) 132renal functional reserve (abst) 206successful in transplant recipients (abst) 441successful outcome, hemodialysis (abst) 132Tamm-Horsfall glycoprotein excretion (abst) 203

Pressor effects on GBM (abst) 295Prevention, progression of renal disease 116Procoagulant

activity of macrophages in GN (abst) 130activity in GN (abst) 134in remnant kidney (abst) 384

Procollagen mRNA, nephrectomy (abst) 370Progressive glomeruloscierosis

chronic serum sickness (abst) 1037Progressive renal disease

rational therapeutic principles 116Progressive renal failure

new antibody-antigen system (abst) 333'251-iothalamate clearance, creatinine (abst) 190

Propionate, cell swelling (abst) 418Prostacyclin production, cAMP (abst) 271

Prostaglandinammoniagenesis in acute respiratory alkalosis (abst)... 401ANF antagonizes release of (abs) 279blockade in denervated kidneys, captopril (abst) 277cAMP and Ca2 signaling systems (abst) 271

Ca2, bradykinin in arterioles (abst) 261DOCA salt treatment on urinary 930GFR, albumin in diabetes (abst) 199glomerular production, GN (abst) 264glucagon, mediates amino acid induced rise in

hemodynamics 1147

hydronephrotic kidney sensitivity to bradykinin 71

hydroxyeicosatetraenoic acids (abst) 265interleukin-l induces natriuresis 1059mesangial cell proliferation, matrix synthesis (abst). . . . 268modulate mesangial cell proliferation (abst) 276Na-K ATPase activity (abst) 417PTH mediated Ca transients (abst) 351

vasopressin antagonists (abst) 251

verapamil, GFR and CyA administration (abst) 355

Prostaglandin E1reversal of proteinuria (abst) 321

Prostaglandin E2cytoprotective effects of (abst) 281

epidermal growth factor mechanism (abst) 274inhibits Na-K-ATPase in IMCD (abst) 268production in diabetic rats with hypertension 1100renal denervation, natriuresis (abst) 280

bath, dialysis (abst)Cail channels in mesangial cells (abst)cell rubidium uptake indexes transport ofchannels in papillary surface epithelium (abst).C1 channel currents in BLM (abst)conductance, muzolimine (abst)depletion alkalosis, PHCO3 (abst)depletion and vasopressin (abst)depletion causes Na retention, high BP (abst)depletion, metabolic acidosis (abst)

164642424428424402431299405

Subject Index: Vol. 33 lxix

vitamin D3 in parathyroid glands (abst) 335zinc balance, zinc deficiency in 1091

Uremiclindane (abst) 199

nephropathy, insights (abst) 334PTH on lymphocyte in (abst) 197

Ureteral excision in rat (abst) 437Ureteral obstruction (abst) 358

management of complications during transplantation(abst) 1040

Urinary abnormalities in CRF (abst) 375Urine

acidification, proton translocating ATPases 767alkali secretion (abst) 399culture of cells, ATN (abst) 364glutathione transferase in the 571nitrogen and phosphate excretion and body mass index

(abst) 383Uroarthritis (abst) 761Urokinase

plasminogen activator (abst) 176

protein kinase (abst) 170Urosepsis, endotoxemia (abst) 212

Valsalva maneuvereffect on ANF release (abst) 269

Vanadate, H-ATPase (abst) 394Vancomycin therapy in CAPD (abst) 136Vascular reactivity, hypertension (abst) 305Vascular smooth muscle cells (abst) 303

desensitation to PAF (abst) 171down regulation of All (abst) 288

Vasculitisrisk factors (abst) 213spectrum if idiopathic renal (abst) 214

Vasoactive agents, adhesion (abst) 157Vasoactive intestinal polypeptide (abst) 288Vasoconstriction

alpha2 adrenoceptor (abst) 414PAF, microcirculatory response (abst) 260

VasopressinAVP in idiopathic nephrotic syndrome (abst) 211BP changes in hypertension (abst) 294Ca and cAMP as second messengers (abst) 286Ca and Na transport (abst) 417dehydration and rehydration (abst) 141demeclocycline effect on cAMP (abst) 252dialysis hypotension (abst) 222energy metabolism (abst) 255genetic linkage, diabetes and DNA marker (abst) . . . . 1035lithium effect on water flow (abst) 263luminal pH effects on K secretion (abst) 426NaC1 and osmotic water permeabilities (abst) 280neuropeptide Y inhibition (abst) 252oxytocin binding sites 959pertussis toxin, Vl receptor (abst) 257phorbol myristate acetata, A23 187 (abst) 252phosphoinositide hydrolysis in LLC-PK1 cells (abst).... 161renal hypertrophy (abst) 264renal prostaglandins (abst) 251resistance to, K depletion (abst) 431selectivity contracts arterioles (abst) 262sensitive cAMP metabolism by Ca (abst) 268sytosolic Ca, LLC-PK2 cells (abst) 289water channel in endocytic vesicles (abst) 175

action, pertussis toxin (abst) 264

enhances K excretion (abst) 426Vein stenosis, subclavian, HD 1156

VerapamilCa absorption (abst) 343CsA interaction (abst) 449PBM and CsA (abst) 455

Vesicoureteric reflux in children (abst) 179Vimentin filament in glomerulus (abst) 134Vitamin B6 deficiency, azotemic (abst) 388Vitamin C supplementation (abst) 382Vitamin D

experimental uremia (abst) 334keto acids in osteodystrophy (abst) 132metabolites after transplantation (abst) 623

Vitamin D3atherogenic role of (abst) 347clearance of calcitriol in ARF 530cytosolic Ca in parathyroid cells (abst) 349cytosolic calcium in parathyroid cells 850essential hypertension (abst) 627hypercalciuric stone formers (abst) 343increases plasma Al in RD 24:S-175interleukin 2 accumulation in T cells (abst) 346phosphorus levels regulated (abst) 346Pi transporter (abst) 350preventing bone disease 24:S-178prevents parathyroid cell proliferation (abst) 344PTH and CRF 1049synthesis and activity of analogs of (abst) 339synthesis in metabolic acidosis (abst) 342

Voltagedependent Cl channel (abst) 422

VolumeCa dependency of hypotonic regulation (abst) 436cell, ADH regulates (abst) 427hypotonic cell, cyclosporine (abst) 368peritoneal dialysate measurements 64regulation in PT (abst) 428regulation, Na pump, K leak (abst) 418regulatory cell decrease (abst) 439regulatory increase, CCT (abst) 436

Vi receptor antagonist (abst) 269

Waterchannel, vasopressin inducible (abst) 175

flow, energy metabolism during vasopressin (abst) .... 255

treatment in dialysis (abst) 223vesicles deliver conducting particles (abst) 261

Wegener' s granulomatosisdialysis and transplant (abst) 1035serological diagnosis of (abst) 760

Xanthine oxidase deficiency (abst) 208

Zincbalance in uremia and zinc deficiency 1091depletion, vitamin D3, phosphate diet (abst) 342

l-deamino-8-D-arginine-vasopressincorrects bleeding in uremia (abst) 142diabetes insipidus (abst) 182

1 ,25-dihydroxycholecalciferolbone turnover during treatment with phosphate

binders 98912-Lipoxygenase, All, Cai (abst) 173

lxx Subject Index: Vol. 33

125 1-iothalamate, RF (abst) . 1901251-SCH23982, DA-1 receptor (abst) 41914, 15-Dihydroxyeicosatrienoic acid

AVP induced conductivity in CCD (abst) 26715-deoxyspergualin (abst) 322

HN (abst) 32415N glutamine metabolism, Fanconi (abst) 39315N, ammoniagenic pathways (abst) 16716-dimethyl prostaglandin E (abst) 4522-bromoethylamine hydrobomide (abst) 367

24,25(OH)D3blunts hypercalcemic effect in CR1 (abst) 347hypercalcemic effect of I ,25(OH)2D3 (abst) 347

29-Nor-aldosterone, excretion (abst) 2733H-metolazone binding, thiazide (abst) 41531P nuclear magnetic resonance (abst) 397

hyponatremia (abst) 1785'-nucleotidase, ischemia (abst) 39699m-technetium-pertechnetate (abst) 41699mTc-DMSA, renal handling (abst) 1034